

Description

Background of the Invention

Field of the Invention

The invention relates to naphthalene derivatives which are useful in inhibiting certain dermatological conditions. This invention also relates to pharmaceutical compositions useful in relieving the effects of certain chronic recurrent papulosquamous dermatoses, e.g., psoriasis. This invention also relates to a process for preparing compounds of this invention.

10 Related Disclosures

Psoriasis is a skin disease characterized in part by excessive proliferation of cells of the epidermis which remain strongly adherent and build up into a scaly plaque typical of the disease. Currently available therapies, which are not curative, depend on the control of epidermal cell proliferation through the use of hormonal agents, such as corticosteroids or through the use of compounds related to cancer


15 chemotherapy such as hydroxyurea, methotrexate, and the nitrogen mustards.

While the above agents are effective to a certain extent, they cause numerous severe undesirable side effects including renal irritation, hepatic toxicity, and erythema.

The compound, 2,3-dimethoxy-1,4-diacetyloxy-naphthalene is known and is disclosed to be useful as a synthetic intermediate, but no useful biological activity has been ascribed to it. See J. Chem. Res., Synop. 1980(4), 156-7 and An. Quim. 1976, 72(3): 247-53. Certain naphthoquinones are known to be useful in treating psoriasis. See, for example, U.S. Patent No. 4,229,478 and British Patent No. 1,243,401. But, these compounds have one or more drawbacks such as causing skin irritation, staining the skin and sensitizing the patient. Surprisingly, it has been discovered that the compounds of the instant invention are less irritating, do not stain the skin and do not sensitize when used in the treatment of psoriasis. Further, the compounds of the present invention are more stable in the topical formulations normally used.

Summary

The present invention relates to a pharmaceutical composition in a form suitable for topical administration to mammals comprising a compound of the following formula



wherein:

R^1 and R^2 are lower alkoxy of one to six carbon atoms or lower alkylthio of one to six carbon atoms; R^3 is hydrogen, lower alkyl of one to six carbon atoms, lower alkoxy of one to six carbon atoms, optionally substituted phenyl, optionally substituted phenyl lower alkyl, optionally substituted phenyl lower alkoxy, amino, lower alkylamino, lower dialkylamino, halo, cyano, or $S(O)_nR$ wherein R is lower alkyl of one to six carbon atoms; optionally substituted phenyl; optionally substituted phenyl lower alkyl; or heterocyclic aryl of three to nine ring atoms containing one or two heteroatoms selected from nitrogen, oxygen and sulfur wherein the heterocyclic aryl is optionally substituted by one or more substituents selected from lower alkyl, lower alkoxy, halo and cyano and the pharmaceutically acceptable acid addition salts thereof; and n is 0, 1 or 2; and

W is alkyl of one to seven carbon atoms.

Another aspect of the invention relates to those compounds for use in relieving the condition of psoriasis in mammals.

Another aspect of the invention is the novel compounds of formula (I) wherein R^1 , R^2 , R^3 , W and n are as defined above with the proviso that R^3 is not hydrogen when R^1 and R^2 are methoxy and W is methyl.

Yet another aspect of the invention is preparing compounds of formula (I) by reacting compounds of formula (XI) (infra) with an acid anhydride.

In a preferred embodiment, R^3 is in the 6-position and is hydrogen, bromo, chloro, fluoro or cyano.

In another preferred embodiment, R^3 is at the 6-position and is bromo, chloro, fluoro, cyano, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, and i-butoxy.

Within this specific embodiment of the instant invention, a preferred group of compounds of formula (I) are those wherein R^1 and R^2 are lower alkoxy of one to three carbon atoms and W is lower alkyl of one to five carbon atoms.

In the present specification and claims the term "alkyl" is intended to mean alkyl groups containing one to seven carbon atoms including straight chain groups, or branched chain groups. Illustrative of such groups are for example, methyl, ethyl, n-propyl, i-propyl, n-hexyl, 2-methylpentyl, and n-heptyl. The term

"lower alkyl" refers to alkyl groups of one to six carbon atoms as defined above. Examples of "lower alkyl" groups are methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, 2,2-dimethylpropyl and t-hexyl. The term "phenyl lower alkyl" refers to an optionally substituted phenyl ring attached to an alkylene chain of one to six carbon atoms.

5 The term "lower alkoxy" refers to a straight or branched chain aliphatic group of one to six carbon atoms having bonded thereto an oxygen moiety. Examples of "lower alkoxy" are methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, s-butoxy, t-butoxy and n-pentyloxy. "Phenyl lower alkoxy" refers to a phenyl ring attached to an alkylene chain of one to six carbon atoms having bonded thereto an oxygen atom. Examples of "phenyl lower alkoxy" are benzyloxy, 4-chlorophenylethoxy and phenyl-n-propoxy.

10 The term "lower alkylthio" refers to a straight or branched chain aliphatic group of one to six carbon atoms having bonded thereto a sulfur moiety. Examples of "lower alkylthio" are methylthio, ethylthio, n-propylthio, i-butylthio and n-hexylthio.

Optionally substituted phenyl refers to a phenyl ring optionally substituted by one or more substituents selected from the group consisting of lower alkyl, lower alkoxy, halo, lower acyl, lower acyloxy, cyano, nitro, amino and lower acylamino.

15 The term "halo" refers to fluoro, chloro, and bromo. The term "cyano" refers to the group —CN . The term "amino" refers to the group —NH_2 .

The term "lower alkylamino" refers to an amino group substituted by lower alkyl as is defined above. Examples of "lower alkylamino" are methylamino, ethylamino and n-butylamino.

20 The term "lower dialkylamino" refers to an amino group substituted by two lower alkyl groups. Examples of "lower dialkylamino" are dimethylamino, dipropylamino and methylethylamino.

The term "lower acyl" refers to the group $\text{R}^4\text{C(O)—}$ wherein R^4 is a lower alkyl group of one to six carbon atoms or an optionally substituted phenyl group. Examples of "lower acyl" are acetyl, propanoyl, butanoyl and benzoyl. The term "lower alkoxy carbonyl alkyl" refers to an ester group of the formula $\text{R}^5\text{OC(O)—}$ substituted on an alkyl group wherein R^5 is lower alkyl as is defined above. Examples of "lower alkoxy carbonyl alkyl" are methoxycarbonylmethyl, ethoxycarbonylmethyl, ethoxycarbonylethyl, propoxycarbonylethyl and the like.

30 The term "heterocyclic aryl" is defined as those cyclic aromatic compounds having 3 to 9 ring carbon atoms and having one or two heteroatoms in the ring selected from the group consisting of nitrogen, oxygen and sulfur. Examples of such include the groups thiapyranyl, benzothiapyranyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, indolyl, guinolyl, indazolyl and the like. These heterocyclic aryls may be optionally substituted with halo, lower alkyl, cyano and lower alkoxy.

By the term "pharmaceutically acceptable acid addition salts" as used in the case of the various R^3 containing heterocyclic aryl substituents herein is intended to mean those non-toxic pharmaceutically acceptable acid addition salts which do not adversely affect the pharmaceutical properties of the parent compounds. With respect to these addition salts, suitable inorganic anions include, for example, chloride, bromide, iodide, sulfate, phosphate, nitrate, and the like. Suitable organic anions include, for example, acetate, benzoate, lactate, picrate, propionate, butyrate, valerate, tartrate, maleate, fumarate, citrate, succinate, tosylate, ascorbate, nicotinate, adipate, gluconate and the like.

40 *Formulation and Administration*

The compositions of the present invention may be formulated for administration in any convenient way by analogy with other topical compositions adapted for use in mammals. These compositions may be presented for use in any conventional manner with the aid of any of a wide variety of pharmaceutical carriers or vehicles.

50 The naphthalenes of formula (I) may be formulated with suitable pharmaceutical vehicles known in the art to form particularly effective topical compositions. An effective amount of the naphthalene compound is about 0.001%w to about 10%w of the total formulated composition. The rest of the formulated composition will be about 90%w to about 99.999%w of a suitable excipient which may include a pharmaceutically acceptable solvent and other pharmaceutically acceptable additives to form a topically effective pharmaceutical formulation.

55 A pharmaceutically acceptable solvent is one which is substantially non-toxic and non-irritating under the conditions used and may be readily formulated into any of the classical drug formulations such as powders, creams, ointments, lotions, gels, foams, aerosols, solutions and the like. Particularly suitable solvents include water, ethanol, acetone, glycerine, propylene carbonate, dimethylsulfoxide (DMSO), and glycols such as 1,2-propylene diol, i.e., propylene glycol, 1,3-propylene diol, polyethylene glycol having a molecular weight of from 100 to 10,000, dipropylene glycol, etc. and mixtures of the aforementioned solvents with each other.

60 A topical cream may be prepared as a semi-solid emulsion of oil in water or water in oil. A cream base formulation by definition is an emulsion, which is a two-phase system with one liquid (for example fats or oils) being dispersed as small globules in another substance (e.g., a glycol-water solvent phase) which may be employed as the primary solvent for the naphthalenes therein. The cream formulation may contain fatty alcohols, surfactants, mineral oil or petrolatum and the typical pharmaceutical adjuvants such as anti-oxidants, antiseptics, or compatible adjuvants. A typical cream base formulation is as follows:

65

	Water/glycol mixture (15% or more glycol)	50—99 parts by weight
	Fatty Alcohol	1—20
5	Non-ionic Surfactant	0—10
	Mineral Oil	0—10
	Typical Pharmaceutical Adjuvants	0—5
10	Active Ingredients	0.001—10

The fatty alcohol, non-ionic surfactant, and other adjuvants are discussed in U.S. 3,934,013 to Poulsen which is incorporated herein by reference.

15 The naphthalenes of formula (I) may also be formulated as topical ointments. A "classical" ointment is a semisolid anhydrous composition which may contain mineral oil, white petrolatum, a suitable solvent such as a glycol and may include propylene carbonate and other pharmaceutically suitable additives such as surfactants, for example Span and Tween, or wool fat (lanolin), along with stabilizers such as antioxidants and other adjuvants as mentioned before. Following is an example of a typical "classical" ointment base:

	White Petrolatum	40—94 parts by weight
	Mineral Oil	5—20
25	Glycol Solvent	1—15
	Surfactant	0—10
30	Stabilizer	0—10
	Active Ingredients	0.001—10.0

Other suitable ointment base formulations which employ propylene carbonate are described in U.S. Patent 4,017,615 issued April 12, 1977 by Shastri et al entitled "Propylene Carbonate Ointment Vehicle" and U.S. 3,924,004 issued December 2, 1975 by Chang et al entitled "Fatty Alcohol-Propylene Carbonate-Glycol Solvent Cream Vehicle". As much of those applications as is pertinent is incorporated herein by reference. Following is a typical ointment base formulation containing propylene carbonate:

40	Active Ingredients	0.001—10.0 parts by weight
	Propylene Carbonate	1—10
	Solvent	1—10
45	Surfactant	0—10
	White Petrolatum	70—97

50 Suitable solvents, surfactants, stabilizers, etc. are discussed in U.S. 3,934,013 and such are incorporated herein by reference.

A suitable topical "non-classical" anhydrous, water washable "ointment type" base is described in U.S. Patent No. 3,592,930 to Katz and Neiman, and that patent is incorporated herein by reference. A representative composition of this invention utilizing such base is as follows:

55	Glycol Solvent	40—35 parts by weight
	Fatty Alcohol	15—45
60	Compatible Plasticizer	0—15
	Compatible Coupling Agent	0—15
	Penetrant	0—20
65	Active Ingredients	0.001—10.0


Another aspect of the invention is a method for relieving the condition of psoriasis in a mammal by topically administering a composition containing a compound of formula (I) wherein R^3 , n , R^1 , and R^2 are as defined above. Generally, the anti-psoriatic manifestation in mammals, particularly humans, is combatted by contacting the inflamed areas with a therapeutically effective amount of the naphthalene-containing compositions of this invention, that is, an amount which results in a lessening of the epidermal cell proliferation (an anti-psoriatic effect). Preferably the naphthalenes are first formulated to prepare a suitable pharmaceutical formulation, as discussed hereinabove, which is then placed in contact with the afflicted area(s). An effective amount of the naphthalene compound will depend upon the particular condition and the mammal receiving the treatment and will vary between 0.001% to 10% by weight of the pharmaceutical composition and preferably will be between 0.01% and 1% by weight of the formulation. Using these levels in the formulation, a therapeutically effective and non-side effect producing amount, i.e. enough to affect an anti-psoriatic response, but not enough to adversely effect the recipient, is applied to the afflicted area(s).

Preparation

The compounds of formula (I) may be prepared from compounds of formula (V) or (VI).

The intermediates of formula (V) or (VI) wherein R^3 is a substituent other than hydrogen may be prepared by the reaction sequence below.

REACTION SEQUENCE I



wherein R^1 , R^2 , and R^3 are as defined above.

Compounds of formula (III) are prepared by starting with a 2,3-dihalonaphthoquinone, preferably 2,3-dichloro-1,4-naphthoquinone (compound of formula (II)), which is available from, i.e., Aldrich Chemical Co., and directly nitrating. The reaction proceeds in the manner known for polycyclic aromatic compounds to yield a mixture of the 5- and 6-nitro-2,3-dichloro-1,4-naphthoquinones, compounds of formula (III). The reaction is conducted typically with concentrated nitric acid in a low pH solvent medium, preferably concentrated sulfuric acid, typically at 20°C to 100°C for a time sufficient to complete the reaction.

Depending on the reaction temperature and times of reaction, ratios of the 5-nitro isomer: 6-nitro isomer mixture may range from 10:1 to 1:10, typically 8:1.

Compounds of formula (IV) are synthesized from 5- and 6-nitro-2,3-dichloro-1,4-naphthoquinone, compound of formula (III), by condensing them with an alkali metal alkoxide, wherein the alkoxy moiety is $R^1 = R^2$. The reaction is preferably conducted in an inert organic solvent such as tetrahydrofuran, dimethylsulfoxide, dimethylformamide and the like at temperatures from about 20°C to about 100°C for a time sufficient to assure completeness of reaction, i.e., for about 2 hours to about 48 hours.

Compounds of formula (IV) wherein $R^1 = R^2$ and is lower alkylthio are prepared from compounds of formula (III) in the same manner as for the alkoxy compounds except that an alkali metal salt of an alkyl mercaptan is substituted for an alkali metal alkoxide.

The compounds of formula (V) are prepared from compounds of formula (IV) by catalytic or non-catalytic reduction processes known in the prior art. Metal-acid reducing agent compositions, such as granulated iron and hydrochloric acid, tin and hydrochloric acid, and the like or neutral reducing agent compositions such as zinc dust and aqueous alcohol or aluminum amalgam and aqueous alcohol as well as organo-metallic reducing agents such as lithium aluminum hydride, sodium borohydride and the like may be used in this reduction. Preferably, the reduction is accomplished by treating the compounds of formula (IV) with excess hydrazine in the presence of a catalytically sufficient amount of palladium, typically on carbon. The reaction readily occurs at room temperature, the time of reaction being governed by the rate of addition of the hydrazine to the reaction mixture such typically being about 1 to about 10 hours.

Compounds of formula (VI) wherein R^3 is hydrogen may be prepared by reacting compound of formula (II) with an alkali metal alkoxide or alkali metal salt of a mercaptan as described hereinabove.

Compounds of formula (VI) wherein R^3 is lower alkylamino or lower dialkylamino are prepared by reacting compounds of formula (V) with an alkyl halide such as methyl iodide by methods well known in the art for alkylating amino groups. The following compounds, for example, may be prepared:

- 6-methylamino-2,3-dimethoxy-1,4-naphthoquinone;
- 6-diethylamino-2,3-dimethoxy-1,4-naphthoquinone;
- 6-ethylmethylamino-2,3-dimethoxy-1,4-naphthoquinone;
- and
- 6-methylamino-2,3-dimethylthio-1,4-naphthoquinone.


Compounds of formula (V) are converted into compounds of formula (VI) where R^3 is halo by adding to the compound of formula (V) in an acidified aqueous solution, a solution of an alkali metal nitrite. This initial reaction forms the diazonium salt at the 5- or 6-position of the naphthoquinone ring. The salt is decomposed with a solution of cuprous halide dispersed or dissolved in the corresponding halogen acid (the Sandmeyer reaction). This classical reaction is treated extensively in Bigelow, Org. Synthesis, Coll. Vol. I, 126—133 (1941).

A modification of the above Sandmeyer reaction is useful in the preparation of the compounds of formula (VI) where R^3 is cyano in that the diazonium salt, rather than being decomposed in the presence of cuprous halide/halogen acid is decomposed in the presence of an alkali metal cyanide and a cuprous halide. See Clarke and Read, Org. Synthesis, Coll. Vol. I, 514 (1941) for a further explanation of the considerations involved in this modified Sandmeyer reaction.

The compounds of formula (VI) where R^3 is an optionally substituted heterocyclic arylthio group, optionally substituted phenylthio or alkylthio may also be prepared from the diazonium salt (above). For example, the diazonium salt of the compound of formula (V) is reacted with an alkali solution of thiophenol to yield the compounds of formula (VI) where R^3 is phenylthio. Typically, the displacement reaction of the diazonium salt is carried out at 30°—75°C by adding an alkali solution of thiophenol in an inert organic solvent. Solvents of preference are the inert solvents such as ethyl acetate, tetrahydrofuran and the like. Reaction times may vary from 10 minutes to about 24 hours.

The heterocyclic arylthio compounds are preferably prepared by adding the 2,3-dialkoxy-5 or 6-nitro-1,4-naphthoquinone of formula (IV) to a solution of the thiol-substituted heterocyclic aryl compound admixed with an alkali metal hydride in an inert organic solvent such as dimethylformamide. The reaction is typically conducted at -75° to -25°C over a period of about 10 to about 60 minutes.

The preferred procedure for the preparation of the compounds of formula (VI) where R^3 is a linear or branched alkylthio or an optionally substituted phenylalkylthio is by first converting a compound of formula (V) to the di(2,3- R^1 , R^2 -1,4-naphthoquinone)-5 or 6-disulfide of the following formula:



wherein R^1 and R^2 are as defined above. A mixture of an alkaline earth or alkali metal thiol carboxylate such as the acetate, propanoate, butanoate and the like (compounds of the formula




25 where y is the integer 0 to 18, M is an alkali or alkaline earth metal and x is the valence of said metal) in an inert organic solvent is added to a solution or dispersion of compound of formula (V) at a temperature of -10 to $+10^\circ\text{C}$ over a period of about 1 to about 120 minutes, preferably 5 to 30 minutes. Reaction media include a variety of polar inert solvents such as dimethylformamide, dimethylsulfoxide and the like. After further reaction, typically for about 1 to about 10 hours at 20° to 50°C , the disulfide is isolated. This compound can then be used to prepare the alkyl or phenylalkyl sulfides of formula (VI) by first treating the disulfide with a mixture of sodium borohydride in an inert organic solvent and adding to such mixture at a temperature of about -10°C to about 75°C for 1 to 10 hours an appropriate alkylating agent such as a dialkyl sulfate, an alkyl halide, an phenylalkyl halide and the like. Illustrative of such alkylating agents are the compounds methyl bromide, methyl iodide, dimethyl sulfate and benzyl bromide. Preferably alkyl iodide is used as the alkylating agent herein.

Where appropriate, salts of the compounds bearing heterocyclic aryl substituents are prepared. For example, the methylsulfate salt of the 2,3-dialkoxy-5-(pyridin-4-ylthio)-1,4-naphthoquinone is readily prepared by admixture with dimethylsulfate in an inert organic solvent such as tetrahydrofuran. Salt formations of this type are well known in the prior art.

A particularly preferred method of preparing compounds of formula (VI) wherein R^3 is 6-halo is shown in the following reaction sequence.

REACTION SEQUENCE II



wherein R^1 and R^2 are as defined above.

14


Compounds of formula (VIII) are prepared according to the method disclosed in J. Am. Chem. Soc., 70, 3165 (1948) and *Ibid.*, 71, 3615 (1949). Halo substituted butadiene is reacted with 1,4-benzoquinone in a solvent such as acetic acid at a temperature of -10°C to 30°C , preferably at 25°C for 24 to 72 hours, preferably from 40 to 48 hours. The 5,7-dihydro compound of formula (VIII) is recovered and treated with an oxidizing agent such as sodium dichromate, sodium nitrite and the like as described in the above articles to form compounds of formula (VIII). Compounds of formula (IX) are prepared by bubbling chlorine gas into a solution of compound of formula (VIII) dissolved in a solvent such as glacial acetic acid, nitrobenzene, carbon tetrachloride and the like, preferably glacial acetic acid at room temperature. This compound, which may be isolated by known means, dissolved in a solvent such as acetic acid is treated with chlorine gas and a suitable catalyst such as sodium acetate, iodine, iron (III) chloride, dimethylformamide or alcohols with heating under reflux for 1/2 to 4 hours, preferably for 1 to 2 1/2 hours to yield compounds of formula (X). Compounds of formula (VI) wherein R^3 is halo are prepared by reacting compound of formula (X) with an alkali metal alkoxide such as sodium alkoxide, e.g., sodium methoxide in an anhydrous solvent such as methanol, dimethylformamide and the like, the solvent being chosen according to the length of the alkyl chain on the alkoxy group. The reaction mixture is heated under reflux for 1/2 to 3 hours, preferably for 1/2 to 1 1/2 hours. Compounds of formula (VI) are recovered by conventional means such as by crystallization.

The compounds of formula (VI) wherein R^1 and R^2 are lower alkylthio may be prepared by the method described for the alkoxy compound except that the alkali metal alkoxide is replaced by the alkali metal salt of the alkyl mercaptan with the solvent being dimethyl-formamide and the like.

The intermediate, 2-chloro-1,3-butadiene (chloroprene) is available from, i.a., Pfaltz and Bauer Chemical Co. 2-Bromo-1,3-butadiene and 2-fluoro-1,3-butadiene may be prepared by methods well known in the art, for example, by the methods discussed in J. Am. Chem. Soc., 55 786 (1933) and U. S. Patent No. 2,401,850, respectively.

The intermediates of formula (VI) wherein R^3 is lower alkyl, lower alkoxy, optionally substituted phenyl, optionally substituted phenyl lower alkyl or optionally substituted phenyl lower alkoxy may be prepared by methods well known in the art such as by reacting the diazonium salt of compound of formula (V) with an appropriate compound such as an alcohol e.g. methanol, ethanol, benzyl alcohol and the like. These intermediates may also be prepared by the method set out in Reaction Sequence (II) wherein the 2-halo-1,3-butadiene is replaced by the appropriate 1,3-butadiene such as 2-methyl-1,3-butadiene (isoprene), 2-ethyl-1,3-butadiene and the like.

Compounds of formula (I) are prepared from compounds of formula (VI) by first reducing to form compounds of formula (XI)



(XI)

by, for example, hydrogenation at atmospheric pressure in the presence of a catalyst such as palladium on charcoal. Alternatively, this reduction may be achieved using $\text{Zn}/\text{acetic acid}$ (preferably for $\text{R}_3=\text{H}$ compounds), NaBH_4 in a solvent such as THF or DME, $\text{Na}_2\text{S}_2\text{O}_8$ in aqueous systems, catalytic transfer hydrogenation with cyclohex (adi)ene, and the like.

The compounds of formula (XI) are then acylated with the required alkanolic acid, or reactive derivative thereof. Suitably this acylation may be carried out using an alkanoyl anhydride and pyridine such as acetic anhydride and the like in a solvent such as tetrahydrofuran, diethyl ether and the like. (Of course, this acylation can, if convenient and with an appropriate choice of reaction conditions, be carried out as part of a one step conversion of a compound of formula (VI) into a compound of formula (I)). Compounds of formula (I) are recovered by recrystallization.

The sulfinylnaphthalenes of formula (I) are prepared by oxidation of the corresponding thio compounds with a stoichiometric amount of a suitable peracid in an inert organic solvent.

The compounds of formula (I) bearing a sulfonyl substituent are prepared by further oxidizing the compounds of formula (I) wherein R^3 is a sulfinyl group with a suitable peracid typically at -10 to 75°C for 1 to 10 hours. Preferably, *m*-chloroperbenzoic acid in an inert organic solvent at room temperature is used to prepare the desired sulfonyl compounds.

The following specific description is given to enable those skilled in the art to more clearly understand and practice the present invention. It should not be considered as a limitation upon the scope of the invention but merely as illustrative and representative thereof.

Preparation 1

2,3-Dichloro-5- and 6-nitro-1,4-naphthoquinone.

(Preparation of Compounds of Formula (III)).

Finely powdered 2,3-dichloro-1,4-naphthoquinone (50 g, 0.22 mol) was added to a stirred mixture of concentrated sulfuric acid (170 ml) and 90% nitric acid (102 ml) at a rate so that the exothermic reaction raised the temperature to 60°C. The resulting mixture was stirred at 60°C for a further 2 hours. The yellow crystalline solid was filtered off, washed thoroughly with water and recrystallized from chloroform giving 22.9 g of the 5-nitro isomer, mp 156—157°C. The above strongly acidic filtrate was poured onto ice water. The resultant solid was filtered off, washed thoroughly with water and dried giving 20.8 g of a mixture of the 5- and 6-isomer. Fractional crystallization of this mixture from acetic acid and chloroform:isopropanol afforded 2.8 g of the 6-nitro isomer, mp 184—187°C.

Further quantities of both 5- and 6-isomer were obtained from the recrystallization mother liquors by chromatography on a silica gel column eluting with chloroform:cyclohexane mixtures.

Preparation 2

2,3-Dimethoxy-5-nitro-1,4-naphthoquinone.

(Preparation of Compounds of Formula (IV)).

A. A solution of 2,3-dichloro-5-nitro-1,4-naphthoquinone (2.72 g, 10 mmol) in anhydrous tetrahydrofuran (15 ml) was added to a solution of 1N sodium methoxide (25 ml, 25 mmol) and the resulting solution stored at 22° for 16 hours. Acetic acid (1 ml) was then added, the solution concentrated in vacuo and the residue partitioned between water (50 ml) and chloroform (100 ml). The aqueous phase was further extracted with chloroform (2 × 50 ml). The combined chloroform extracts were dried with MgSO₄ and concentrated in vacuo. The residue was recrystallized from methanol giving 1.99 g of 2,3-dimethoxy-5-nitro-1,4-naphthoquinone, mp 156—157°.

B. Similarly, using the above procedure in Part A, substituting 2,3-dichloro-6-nitro-1,4-naphthoquinone, where appropriate, for 2,3-dichloro-5-nitro-1,4-naphthoquinone and the appropriate sodium alkoxide for sodium methoxide, the following compounds are prepared:

- 2,3-dimethoxy-6-nitro-1,4-naphthoquinone, mp 113—114°C;
- 2,3-diethoxy-5-nitro-1,4-naphthoquinone;
- 2,3-diethoxy-6-nitro-1,4-naphthoquinone;
- 2,3-di-n-propoxy-5-nitro-1,4-naphthoquinone;
- 2,3-di-n-propoxy-6-nitro-1,4-naphthoquinone;
- 2,3-di-i-propoxy-5-nitro-1,4-naphthoquinone;
- 2,3-di-i-propoxy-6-nitro-1,4-naphthoquinone;
- 2,3-di-n-butoxy-5-nitro-1,4-naphthoquinone;
- 2,3-di-n-butoxy-6-nitro-1,4-naphthoquinone;
- 2,3-di-s-butoxy-5-nitro-1,4-naphthoquinone;
- 2,3-di-s-butoxy-6-nitro-1,4-naphthoquinone;
- 2,3-di-n-pentyloxy-5-nitro-1,4-naphthoquinone;
- 2,3-di-n-pentyloxy-6-nitro-1,4-naphthoquinone;
- 2,3-di-s-pentyloxy-5-nitro-1,4-naphthoquinone;
- 2,3-di-s-pentyloxy-6-nitro-1,4-naphthoquinone;
- 2,3-di-n-hexyloxy-5-nitro-1,4-naphthoquinone;
- 2,3-di-n-hexyloxy-6-nitro-1,4-naphthoquinone;
- 2,3-di-i-hexyloxy-5-nitro-1,4-naphthoquinone;
- 2,3-di-i-hexyloxy-6-nitro-1,4-naphthoquinone;
- 2,3-di(2,2-dimethylpropoxy)-5-nitro-1,4-naphthoquinone; and
- 2,3-di(2,2-dimethylpropoxy)-6-nitro-1,4-naphthoquinone.

C. Similarly, using the above procedure in Part A, substituting 2,3-dichloro-6-nitro-1,4-naphthoquinone, where appropriate, for 2,3-dichloro-5-nitro-1,4-naphthoquinone and the appropriate sodium salt of alkylmercaptan for sodium methoxide, the following compounds, for example, are prepared:

- 2,3-dimethylthio-6-nitro-1,4-naphthoquinone;
- 2,3-di-i-propylthio-6-nitro-1,4-naphthoquinone; and
- 2,3-di-n-hexylthio-6-nitro-1,4-naphthoquinone.

Preparation 3

2,3-Dimethoxy-5-amino-1,4-naphthoquinone.

(Preparation of Compounds of Formula (V)).

Hydrazine (4.0 ml, 125 mmol of 97%) was added dropwise, over a 2 hour period, to a stirred mixture of the captioned compound of Preparation 2 (19.9 g, 75.6 mmol), 5% palladium on carbon (10 g) and ethanol (750 ml) in a nitrogen atmosphere. The catalyst was filtered off through a celite pad that was washed with hot ethanol (2 × 300 ml). The combined filtrate and washings were concentrated to dryness in vacuo and the residue recrystallized from water:ethanol (1.5:1) giving 14.6 g of 2,3-dimethoxy-5-amino-1,4-naphthoquinone, mp 116—117°.

Similarly, substituting the compounds from Preparation 2 for 2,3-dimethoxy-5-nitro-1,4-naphtho-

quinone the following compounds are prepared:

- 2,3-dimethoxy-6-amino-1,4-naphthoquinone, mp 196—197°C;
- 2,3-diethoxy-5-amino-1,4-naphthoquinone;
- 2,3-diethoxy-6-amino-1,4-naphthoquinone;
- 2,3-di-n-propoxy-5-amino-1,4-naphthoquinone;
- 2,3-di-n-propoxy-6-amino-1,4-naphthoquinone;
- 2,3-di-i-propoxy-5-amino-1,4-naphthoquinone;
- 2,3-di-i-propoxy-6-amino-1,4-naphthoquinone;
- 2,3-di-n-butoxy-5-amino-1,4-naphthoquinone;
- 2,3-di-n-butoxy-6-amino-1,4-naphthoquinone;
- 2,3-di-s-butoxy-5-amino-1,4-naphthoquinone;
- 2,3-di-s-butoxy-6-amino-1,4-naphthoquinone;
- 2,3-di-n-pentyloxy-5-amino-1,4-naphthoquinone;
- 2,3-di-n-pentyloxy-6-amino-1,4-naphthoquinone;
- 2,3-di-s-pentyloxy-5-amino-1,4-naphthoquinone;
- 2,3-di-s-pentyloxy-6-amino-1,4-naphthoquinone;
- 2,3-di-n-hexyloxy-5-amino-1,4-naphthoquinone;
- 2,3-di-n-hexyloxy-6-amino-1,4-naphthoquinone;
- 2,3-di-i-hexyloxy-5-amino-1,4-naphthoquinone;
- 2,3-di-i-hexyloxy-6-amino-1,4-naphthoquinone;
- 2,3-di(2,2-dimethylpropoxy)-5-amino-1,4-naphthoquinone;
- 2,3-di(2,2-dimethylpropoxy)-6-amino-1,4-naphthoquinone;
- 2,3-dimethylthio-6-amino-1,4-naphthoquinone;
- 2,3-di-i-propylthio-6-amino-1,4-naphthoquinone; and
- 2,3-di-n-hexylthio-6-amino-1,4-naphthoquinone.

Preparation 4

5-Chloro-2,3-dimethoxy-1,4-naphthoquinone.

(Preparation of Compounds of Formula (VI) where R³ is 5-chloro).

- A solution of sodium nitrite (0.69 g, 10 mmol) in water (5 ml) was added at 0—5°C to a solution of 5-amino-2,3-dimethoxy-1,4-naphthoquinone (1.17 g, 5 mmol) in 5:1 acetic acid:water (25 ml) containing concentrated hydrochloric acid (1.7 ml). A further quantity of sodium nitrite (0.69 g) was then added to the reaction mixture after cooling to -5°C, followed by a solution of cuprous chloride (0.6 g) in concentrated hydrochloric acid (5 ml). The mixture was allowed to warm to 22°C and solid cuprous chloride was added portionwise until the mixture assumed a green color. Water was then added to the reaction mixture and the precipitated yellow solid filtered off, washed with water and recrystallized from methanol:water (2:1) giving 1.01 g of 5-chloro-2,3-dimethoxy-1,4-naphthoquinone, mp 120—121°C.

Similarly, proceeding as above substituting the appropriate compounds for 2,3-dimethoxy-5-amino-1,4-naphthoquinone the following compound are prepared:

- 6-chloro-2,3-dimethoxy-1,4-naphthoquinone;
- 5-chloro-2,3-diethoxy-1,4-naphthoquinone;
- 6-chloro-2,3-diethoxy-1,4-naphthoquinone;
- 5-chloro-2,3-di-n-propoxy-1,4-naphthoquinone;
- 6-chloro-2,3-di-n-propoxy-1,4-naphthoquinone;
- 5-chloro-2,3-di-i-propoxy-1,4-naphthoquinone;
- 6-chloro-2,3-di-i-propoxy-1,4-naphthoquinone;
- 5-chloro-2,3-di-n-butoxy-1,4-naphthoquinone;
- 6-chloro-2,3-di-n-butoxy-1,4-naphthoquinone;
- 5-chloro-2,3-di-s-butoxy-1,4-naphthoquinone;
- 6-chloro-2,3-di-s-butoxy-1,4-naphthoquinone;
- 5-chloro-2,3-di-n-pentyloxy-1,4-naphthoquinone;
- 6-chloro-2,3-di-n-pentyloxy-1,4-naphthoquinone;
- 5-chloro-2,3-di-s-pentyloxy-1,4-naphthoquinone;
- 6-chloro-2,3-di-s-pentyloxy-1,4-naphthoquinone;
- 5-chloro-2,3-di-n-hexyloxy-1,4-naphthoquinone;
- 6-chloro-2,3-di-n-hexyloxy-1,4-naphthoquinone;
- 5-chloro-2,3-di-i-hexyloxy-1,4-naphthoquinone;
- 6-chloro-2,3-di-i-hexyloxy-1,4-naphthoquinone;
- 5-chloro-2,3-di(2,2-dimethylpropoxy)-1,4-naphthoquinone;
- 6-chloro-2,3-di(2,2-dimethylpropoxy)-1,4-naphthoquinone;
- 6-methoxy-2,3-dimethoxy-1,4-naphthoquinone;
- 6-ethoxy-2,3-diethoxy-1,4-naphthoquinone;
- 6-i-butoxy-2,3-dimethoxy-1,4-naphthoquinone;
- 6-phenylethoxy-2,3-dimethoxy-1,4-naphthoquinone;
- 6-chloro-2,3-dimethylthio-1,4-naphthoquinone;

6-chloro-2,3-di-i-propylthio-1,4-naphthoquinone; and
6-chloro-2,3-di-n-hexylthio-1,4-naphthoquinone;

Preparation 5

5-Cyano-2,3-dimethoxy-1,4-naphthoquinone.

(Preparation of Compounds of Formula (VI) where R³ is cyano).

A solution of sodium nitrite (2.21 g, 32 mmol) in water (6 ml) was added at 0–5°C to a stirred suspension of 5-amino-2,3-dimethoxy-1,4-naphthoquinone (3.73 g, 16 mmol) in 3:1 water:tetrahydrofuran (20 ml) containing concentrated hydrochloric acid (6.7 ml) and the resulting mixture was stirred at 0–5°C for a further 1-1/4 hour. The almost clear solution is then neutralized with sodium carbonate, filtered and added at 5°C to a vigorously stirred solution of cuprous chloride (4.75 g) and sodium cyanide (5.88 g) in water (80 ml). Ethyl acetate (100 ml) was added and the mixture is heated at 45°C for 0.5 hours, filtered through a celite bed and separated into the two phases. The aqueous phase was extracted with ethyl acetate (2 × 100 ml). The combined organic phases were extracted with brine (150 ml), dried over MgSO₄ and concentrated to dryness in vacuo. The residue was recrystallized from isopropanol giving 2.96 g of 5-cyano-2,3-dimethoxy-1,4-naphthoquinone, mp 171–172°C.

Similarly, proceeding as above the following compound is prepared:

6-cyano-2,3-dimethoxy-1,4-naphthoquinone.

Preparation 6

Di-(2,3-dimethoxy-1,4-naphthoquinone-5)-disulfide.

(Preparation of Compounds of Formula (VII)).

A slurry of potassium thioacetate (1.5 g, 13.1 mmol) in dimethylformamide (25 ml) was added over 10 minutes to a solution at 0–5°C of 5-amino-2,3-dimethoxy-1,4-naphthoquinone (2.63 g, 10 mmol) in dimethylformamide (25 ml). The mixture was allowed to warm to 22°C and, after 2 hours, an additional quantity of potassium thioacetate (1.25 g) was added. After a further 45 minute reaction, the mixture was added to ice water (500 ml) that was adjusted to pH 6 with acetic acid. The precipitated solid was filtered off, washed with water and recrystallized from chloroform:methanol (1:1) giving 1.32 g. of di(2,3-dimethoxy-1,4-naphthoquinone-5)-disulfide, mp 220–221°C.

Preparation 7

2,3-Dimethoxy-5-phenylthio-1,4-naphthoquinone.

(Preparation of Compounds of Formula (VI) where R³ is phenylthio).

Method A. Sodium nitrite (0.18 g) was added at 0–5°C to a stirred suspension of 5-amino-2,3-dimethoxy-1,4-naphthoquinone (233 mg, 1 mmol) in 0.6N hydrochloric acid (10 ml) and tetrahydrofuran (1 ml). The mixture was stirred at 5°C for 10 minutes until a clear solution was obtained and was then neutralized by the addition of sodium carbonate. The ice cold solution was then slowly added to a vigorously stirred two-phase mixture in a nitrogen atmosphere at 50°C composed of potassium hydroxide (0.16 g), water (10 ml), thiophenol (0.32 ml) and ethyl acetate (35 ml). After a total reaction time of 20 min, the mixture was partitioned between ethyl acetate (40 ml) and brine (100 ml). The ethyl acetate phase was dried over MgSO₄ and concentrated in vacuo. The residue was purified by chromatography on a thick layer silica gel plate using acetone:toluene:chloroform (1:20:20) giving a solid that, after recrystallizing from isopropanol, afforded 70 mg of 2,3-dimethoxy-5-phenylthio-1,4-naphthoquinone, mp 76–77°C.

Similarly, using imidazolyl-2-thiol in place of thiophenol, 2,3-dimethoxy-5-(imidazol-2-yl)thio-1,4-naphthoquinone, mp 97–100°C, was prepared.

Method B. Thiophenol (6.0 ml, 59 mmol) was added at –30°C to a stirred mixture of 100% sodium hydride (1.4 g, 59 mmol) and dimethylformamide (200 ml) and the resulting mixture was stirred at 22°C for 16 hours. This mixture was then cooled to –50°C and a solution of di(2,3-dimethoxy-1,4-naphthoquinone-5)-disulfide (13.0 g, 49 mmol) in dimethylformamide (100 ml) was added over 30 min. The resulting mixture was allowed to warm to 22°C over 1 hour before being cooled to –50°C and neutralized with acetic acid (5.4 ml, 90 mmol). The reaction mixture was then poured into a mixture of water (1.8 l) and methanol (700 ml). The precipitated material was filtered off and recrystallized from methanol giving 10.3 g of 2,3-dimethoxy-5-phenylthio-1,4-naphthoquinone, mp 76–79°C. A further amount (2.2 g) mp 76–77°C was obtained in a second crop from the recrystallization.

Similarly, substituting of the appropriate thiol for thiophenol and the appropriate compound from Preparation 3, the following compounds are prepared:

- 2,3-dimethoxy-6-(2-chlorophenylthio)-1,4-naphthoquinone;
- 2,3-dimethoxy-5-(3-chlorophenylthio)-1,4-naphthoquinone, mp 125–126°C;
- 2,3-dimethoxy-6-(4-chlorophenylthio)-1,4-naphthoquinone;
- 2,3-dimethoxy-5-(2,6-dichlorophenylthio)-1,4-naphthoquinone, mp 158–159°C;
- 2,3-dimethoxy-5-(4-fluorophenylthio)-1,4-naphthoquinone, mp 124–125°C;
- 2,3-dimethoxy-5-(2-bromophenylthio)-1,4-naphthoquinone, mp 152–153°C;
- 2,3-dimethoxy-6-(4-bromophenylthio)-1,4-naphthoquinone;
- 2,3-diethoxy-6-(4-methoxyphenylthio)-1,4-naphthoquinone;
- 2,3-di-n-propoxy-6-(4-nitrophenylthio)-1,4-naphthoquinone;

2,3-di-n-butoxy-6-(2-ethylphenylthio)-1,4-naphthoquinone;
 2,3-di-n-pentyloxy-6-pyridin-2-ylthio-1,4-naphthoquinone;
 2,3-di-n-hexyloxy-6-pyridin-4-ylthio-1,4-naphthoquinone; and
 2,3-dimethoxy-5-(4-acetylaminophenylthio)-1,4-naphthoquinone, mp 118—127°C.

Preparation 8

2,3-Dimethoxy-5-methylthio-1,4-naphthoquinone.

(Preparation of Compounds of Formula (VI) where R³ is methylthio).

Sodium borohydride (100 mg) was added portionwise to a stirred suspension of di(2,3-dimethoxy-1,4-naphthoquinone-5)-disulfide (0.5 g, 1 mmol) in 7:1 tetrahydrofuran:isopropanol (40 ml) in a nitrogen atmosphere until TLC analysis indicated that no starting material remains. Methyl iodide (0.2 ml) was then added and, after 5 minutes, the reaction mixture was poured into ice water (300 ml). 10% Ferric chloride (10 ml) was subsequently added. The precipitated solid was filtered off, washed with water and recrystallized from isopropanol giving 0.36 g of 2,3-dimethoxy-5-methylthio-1,4-naphthoquinone, mp 112—113°C.

By substituting other alkyl iodides for methyl iodide the following are prepared:

2,3-dimethoxy-6-methylthio-1,4-naphthoquinone;
 2,3-dimethoxy-5-benzylthio-1,4-naphthoquinone, m.p. 142—143°C;
 2,3-dimethoxy-6-ethylthio-1,4-naphthoquinone; and
 2,3-dimethoxy-5-methoxycarbonylmethylthio-1,4-naphthoquinone, m.p. 119—120°C.

Preparation 9

2,3-Dimethoxy-5-(4-methylpyridiniumthio)-1,4-naphthoquinone methyl sulfate.

A mixture of dimethylsulfate (0.19 ml, 2 mmol) and 2,3-dimethoxy-5-(4-methylpyridinylthio)-1,4-naphthoquinone (327 mg, 1 mmol) in tetrahydrofuran (10 ml) was heated under reflux for 3 hours and then cooled to 20°C. The orange solid was filtered off, washed with tetrahydrofuran and recrystallized from ethanol:isopropanol giving 279 mg of 2,3-dimethoxy-5-(4-methylpyridiniumthio)-1,4-naphthoquinone methyl sulfate mp 160—162°C and a second crop of 110 mg.

Similarly prepared is 2,3-dimethoxy-5-(2-methylpyridiniumthio)-1,4-naphthoquinone methyl sulfate.

Similarly, the following compounds are prepared by the above method:

2,3-dimethoxy-5-(2-methylpyridiniumsulfinyl)-1,4-naphthoquinone methyl sulfate, m.p. 175—176°C;
 and
 2,3-dimethoxy-5-(4-methylpyridiniumsulfinyl)-1,4-naphthoquinone methyl sulfate, m.p. 175—176°C.

Preparation 10

(Preparation of compounds of formula (X) wherein R³ is 6-chloro)

A. Into a solution of 6-chloro-1,4-naphthoquinone (193 g) in glacial acetic acid (1600 mL) was bubbled chlorine gas until TLC of an aliquot showed complete disappearance of 6-chloro-1,4-naphthoquinone. The resulting precipitate was collected by filtration, and washed with acetic acid (200 mL) and hexane (2 × 300 mL) and air dried to yield the 2,3,6-trichloro-2,3-dihydro-1,4-naphthoquinone (157 g). The solid was transferred into a flask equipped with a mechanical stirrer and reflux condenser. Sodium acetate (98.4 g) and acetic acid (1.5 L) were added, and into the suspension was bubbled chlorine gas. The mixture was brought to reflux and maintained there for 2 hours. The cooled mixture was poured over water (3.5 L), and the resulting precipitate was collected by filtration, and was washed with water (2 × 500 mL), air dried and then vacuum dried over phosphorus pentoxide, to yield 2,3,6-trichloro-1,4-naphthoquinone (139 g), mp 147.5—148.5°C.

Similarly, using the above procedure are prepared:

6-bromo-2,3-dichloro-1,4-naphthoquinone;
 6-fluoro-2,3-dichloro-1,4-naphthoquinone;
 6-methyl-2,3-dichloro-1,4-naphthoquinone;
 6-i-propyl-2,3-dichloro-1,4-naphthoquinone;
 6-phenyl-2,3-dichloro-1,4-naphthoquinone; and
 6-benzyl-2,3-dichloro-1,4-naphthoquinone.

B. Into a suspension of 6-chloro-1,4-naphthoquinone (100 g, 520 mmol) in acetic acid (800 mL) heated to 70°C with mechanical stirring was bubbled chlorine gas. Heating was increased to bring the mixture to reflux, at which time solid iodine (13.2 g, 104 mmol, 0.2 eq.) was added. Chlorine addition at reflux was continued until TLC showed complete conversion to product, 7—10 hours total. The reaction was cooled to give a thick precipitate of product, collected by filtration. A second crop was obtained by concentration and/or dilution with water. Total yield of dried product 2,3,6-trichloro-1,4-naphthoquinone is 121.2 g (464 mmol, 89%), mp 147.5—148.5°C. Anal. Calcd. for C₁₀H₃Cl₃O₂: C, 45.93; H, 1.17; Cl, 40.67. Found: C, 46.05; H, 1.17; Cl, 40.56.

Preparation 11

(Preparation of compounds of formula (VI) wherein R³ is 6-chloro)

To a mechanically stirred solution of sodium methoxide (55.5 g) in anhydrous methanol (1.5 L) under a

blanket of nitrogen was added 2,3,6-trichloro-1,4-naphthoquinone from Preparation 10 (130 g) as rapidly as possible. The temperature rose to 50°C during the addition, and the reaction was then heated to reflux for 1 hour. The mixture was cooled and acidified with 6 M hydrochloric acid to give a brilliant yellow color. After the addition of water (300 mL), the reaction mixture was filtered, and the precipitate was washed with aqueous methanol (4:1 water-methanol) until the filtrate was yellow-orange. The precipitate was air dried to yield 6-chloro-2,3-dimethoxy-1,4-naphthoquinone (102 g), mp 125—126°C.

Similarly, using the above procedure, the following compounds are prepared:

- 6-bromo-2,3-dimethoxy-1,4-naphthoquinone;
- 6-fluoro-2,3-dimethoxy-1,4-naphthoquinone;
- 6-chloro-2,3-diethoxy-1,4-naphthoquinone;
- 6-methyl-2,3-dimethoxy-1,4-naphthoquinone;
- 6-*i*-propyl-2,3-dimethoxy-1,4-naphthoquinone;
- 6-phenyl-2,3-dimethoxy-1,4-naphthoquinone; and
- 6-benzyl-2,3-dimethoxy-1,4-naphthoquinone.

Preparation 12

A. To a solution of sodium-*n*-butoxide (25.8 g) in dry dimethylformamide (125 ml) was added 2,3,6-trichloro-1,4-naphthoquinone (28 g) in one amount. The mixture was refluxed for 2 hours, then cooled, acidified with 6 M hydrochloric acid and evaporated. The residue was chromatographed over silica gel using dichloromethane as eluant to yield 2,3-di-*n*-butyloxy-6-chloro-1,4-naphthoquinone (12.3 g) as a red oily solid.

B. Similarly, proceeding as above in Part A, substituting the appropriate compound for 2,3,6-trichloro-1,4-naphthoquinone and the appropriate sodium alkoxide for sodium-*n*-butoxide, the following compounds are prepared:

- 6-chloro-2,3-di-*i*-butoxy-1,4-naphthoquinone;
- 6-chloro-2,3-(2,2-dimethylpropoxy)-1,4-naphthoquinone;
- 2,3-di-*s*-butoxy-1,4-naphthoquinone;
- 2,3-di(2,2-dimethylpropoxy)-1,4-naphthoquinone; and
- 2,3-di-*n*-hexyloxy-1,4-naphthoquinone.

C. Similarly, proceeding as above in Part A, substituting the appropriate sodium salt of alkyl mercaptan for sodium-*n*-butoxide, the following compounds, for example, are prepared:

- 6-chloro-2,3-dimethylthio-1,4-naphthoquinone;
- 6-chloro-2,3-di-*i*-propylthio-1,4-naphthoquinone;
- 6-chloro-2,3-di-*n*-hexylthio-1,4-naphthoquinone; and
- 2,3-dimethylthio-1,4-naphthoquinone.

Preparation 13

(Compound of formula (VI) wherein R³ is hydrogen)

To a mechanically stirred solution of sodium methoxide (11.1 g) in anhydrous methanol (200 mL) under a blanket of nitrogen was added 2,3-dichloro-1,4-naphthoquinone (22.7 g) as rapidly as possible. The temperature rose to 50°C during the addition, and the reaction was then heated to reflux for 1 hour. The mixture was cooled and acidified with 6 M hydrochloric acid to give a brilliant yellow color. After the addition of water (800 mL), the reaction mixture was filtered, and the precipitate was washed with aqueous methanol (4:1 water-methanol) until the filtrate was yellow-orange. The precipitate was air dried to yield 21.2 g of 2,3-dimethoxy-1,4-naphthoquinone, m.p. 116—117°C.

Similarly, substituting the appropriate sodium alkoxide for sodium methoxide the following compounds are prepared:

- 2,3-diethoxy-1,4-naphthoquinone;
- 2,3-di-*n*-propoxy-1,4-naphthoquinone;

Example 1

A. A solution of 6-chloro-2,3-dimethoxy-1,4-naphthoquinone (50.5 g, 200 mmol) in tetrahydrofuran (500 mL) was hydrogenated at atmospheric pressure over palladium-on-charcoal (10%, 5.0 g) until the solution was colorless, approximately 4 hours.

B. While still under a blanket of hydrogen, a solution of acetic anhydride (47 mL) pyridine (40 mL) and DMAP (1.22 g) in tetrahydrofuran (50 mL) was added to the mixture. After stirring for 1 hour, the mixture was evaporated. The residue was dissolved in ether (500 mL) and was washed with 1 M HCl (3 × 250 mL) and with brine (2 × 250 mL). The organic layer was dried over sodium sulfate, filtered, and evaporated to give an oil which crystallized at high vacuum. Recrystallization from ether-petroleum ether afforded 6-chloro-1,4-diacetyloxy-2,3-dimethoxynaphthalene, m.p. 93—94°C.

Similarly, using the above procedure substituting the appropriate compound of formula (VI) for 6-chloro-2,3-dimethoxy-1,4-naphthoquinone, where appropriate, and the appropriate acid anhydride for acetic anhydride, where appropriate, the following compounds are prepared:

- 6-chloro-2,3-dimethoxy-1,4-di-*n*-propanoyloxynaphthalene;
- 6-chloro-2,3-dimethoxy-1,4-di-*i*-butanoyloxynaphthalene;

6-chloro-2,3-dimethoxy-1,4-di(2,2-dimethylpropanoyloxy)naphthalene;
 6-chloro-2,3-dimethoxy-1,4-di-n-octanoyloxynaphthalene;
 6-chloro-2,3-di-n-butoxy-1,4-diacetyloxynaphthalene;
 6-chloro-2,3-di-s-butoxy-1,4-diacetyloxynaphthalene;
 6-chloro-2,3-di(2,2-dimethylpropoxy)-1,4-diacetyloxynaphthalene;
 2,3-di-n-butoxy-1,4-di-n-pentoyloxynaphthalene;
 6-chloro-2,3-di-n-propoxy-1,4-dipropoxyloxynaphthalene;
 6-chloro-2,3-di-i-propoxy-1,4-dioctanoyloxynaphthalene;
 6-bromo-2,3-dimethoxy-1,4-diacetyloxynaphthalene;
 6-fluoro-2,3-dimethoxy-1,4-diacetyloxynaphthalene;
 5-chloro-2,3-dimethoxy-1,4-diacetyloxynaphthalene;
 5-cyano-2,3-dimethoxy-1,4-diacetyloxynaphthalene;
 6-cyano-2,3-dimethoxy-1,4-diacetyloxynaphthalene;
 6-methylamino-2,3-dimethoxy-1,4-diacetyloxynaphthalene;
 6-diethylamino-2,3-dimethoxy-1,4-dipropoxyloxynaphthalene;
 6-ethylmethylamino-2,3-dimethoxy-1,4-di-n-butanoyloxynaphthalene;
 6-methoxy-2,3-dimethoxy-1,4-di-n-pentanoyloxynaphthalene;
 6-ethoxy-2,3-diethoxy-1,4-di-n-hexanoyloxynaphthalene;
 6-i-butoxy-2,3-dimethoxy-1,4-di(2,2-dimethylpropanoyloxy)naphthalene;
 6-phenylethoxy-2,3-dimethoxy-1,4-diacetyloxynaphthalene;
 6-methyl-2,3-dimethoxy-1,4-diacetyloxynaphthalene;
 6-i-propyl-2,3-dimethoxy-1,4-di-n-octanoyloxynaphthalene;
 6-phenyl-2,3-dimethoxy-1,4-diacetyloxynaphthalene;
 6-benzyl-2,3-dimethoxy-1,4-dipropoxyloxynaphthalene;
 5-chloro-2,3-di-n-pentyloxy-1,4-di-n-butanoyloxynaphthalene;
 5-chloro-2,3-di-s-pentyloxy-1,4-diacetyloxynaphthalene;
 5-chloro-2,3-di-n-hexyloxy-1,4-di-n-octanoyloxynaphthalene;
 5-chloro-2,3-di-i-hexyloxy-1,4-diacetyloxynaphthalene;
 6-chloro-2,3-dimethylthio-1,4-diacetyloxynaphthalene;
 6-chloro-2,3-di-i-propylthio-1,4-diacetyloxynaphthalene;
 6-chloro-2,3-di-n-hexylthio-1,4-diacetyloxynaphthalene;
 2,3-dimethoxy-6-(2-chlorophenylthio)-1,4-diacetyloxynaphthalene;
 2,3-dimethoxy-5-(3-chlorophenylthio)-1,4-diacetyloxynaphthalene;
 2,3-dimethoxy-6-(4-chlorophenylthio)-1,4-diacetyloxynaphthalene;
 2,3-dimethoxy-5-(2,6-dichlorophenylthio)-1,4-diacetyloxynaphthalene;
 2,3-dimethoxy-5-(4-fluorophenylthio)-1,4-diacetyloxynaphthalene;
 2,3-dimethoxy-5-(2-bromophenylthio)-1,4-diacetyloxynaphthalene;
 2,3-dimethoxy-6-(4-bromophenylthio)-1,4-diacetyloxynaphthalene;
 2,3-diethoxy-6-(4-methoxyphenylthio)-1,4-diacetyloxynaphthalene;
 2,3-dipropoxy-6-(4-nitrophenylthio)-1,4-diacetyloxynaphthalene;
 2,3-di-n-butoxy-6-(2-ethylphenylthio)-1,4-diacetyloxynaphthalene;
 2,3-di-n-pentyloxy-6-pyridin-2-ylthio-1,4-diacetyloxynaphthalene;
 2,3-di-n-hexyloxy-6-pyridin-4-ylthio-1,4-diacetyloxynaphthalene; and
 2,3-dimethoxy-5-(4-acetylaminophenylthio)-1,4-diacetyloxynaphthalene.

Example 2

A solution of 2,3-dimethoxy-1,4-naphthoquinone (20.0 g) in tetrahydrofuran (150 mL) was hydrogenated at atmospheric pressure over Pd-C (10%, 0.5 g) until the solution was colorless, approximately 4 hours. While still under a blanket of hydrogen, a solution of acetic anhydride (20 mL) and pyridine (18 mL) in tetrahydrofuran (50 mL) was added to the mixture. After stirring for 1 hour, the mixture was evaporated. The residue was dissolved in ether (100 mL) and was washed with 1 M hydrochloric acid (3 x 50 mL) and with brine (2 x 50 mL). The organic layer was dried over sodium sulfate, filtered, and evaporated. Recrystallization from ether afforded 2,3-dimethoxy-1,4-diacetyloxynaphthalene (22.5 g), m.p. 138—139°C.

Similarly proceeding as above, substituting the appropriate compound for 2,3-dimethoxy-1,4-naphthoquinone and the appropriate acid anhydride, where appropriate, for acetic anhydride, the following compounds, for example, are prepared:

2,3-di-n-propoxy-1,4-di-n-propanoyloxynaphthalene;
 2,3-di-s-butoxy-1,4-di-i-butanoyloxynaphthalene;
 2,3-di(2,2-dimethylpropoxy)-1,4-di-n-pentanoyloxynaphthalene;
 2,3-di-n-hexyloxy-1,4-di(2,2-dimethylpropanoyloxy)naphthalene;
 2,3-dimethoxy-1,4-di-n-propanoyloxynaphthalene;
 2,3-diethoxy-1,4-diacetyloxynaphthalene; and
 2,3-dimethylthio-1,4-diacetyloxynaphthalene.

Example 3

(Preparation of Compounds of Formula (I) where R³ is phenylsulfinyl).

Forty percent (w/v) peracetic acid in acetic acid (1 ml) is added over 30 minutes to a solution of 2,3-dimethoxy-5-phenylthio-1,4-diacetyloxynaphthalene (0.98 g, 3 mmol) in methylene chloride (15 ml). Excess peracetic acid is destroyed by the addition of a few milligrams of 5% palladium on carbon and the mixture filtered through a celite bed. The filtrate is concentrated in vacuo and the residue recrystallized from methanol giving 0.59 g of 2,3-dimethoxy-5-phenylsulfinyl-1,4-diacetyloxynaphthalene.

Similarly, using either peracetic acid or m-chloroperbenzoic acid, the following compounds are prepared from the respective thio compounds:

2,3-dimethoxy-5-(imidazol-2-ylsulfinyl)-1,4-diacetyloxynaphthalene;
 2,3-dimethoxy-6-(2-chlorophenylsulfinyl)-1,4-diacetyloxynaphthalene;
 2,3-dimethoxy-5-(3-chlorophenylsulfinyl)-1,4-diacetyloxynaphthalene;
 2,3-dimethoxy-6-(4-chlorophenylsulfinyl)-1,4-diacetyloxynaphthalene;
 2,3-dimethoxy-5-(2,6-dichlorophenylsulfinyl)-1,4-diacetyloxynaphthalene;
 2,3-dimethoxy-5-(4-fluorophenylsulfinyl)-1,4-diacetyloxynaphthalene;
 2,3-dimethoxy-5-(2-bromophenylsulfinyl)-1,4-diacetyloxynaphthalene;
 2,3-dimethoxy-5-(4-bromophenylsulfinyl)-1,4-diacetyloxynaphthalene;
 2,3-diethoxy-6-(4-methoxyphenylsulfinyl)-1,4-diacetyloxynaphthalene;
 2,3-dipropoxy-6-(4-nitrophenylsulfinyl)-1,4-diacetyloxynaphthalene;
 2,3-di-n-butoxy-6-(2-ethylphenylsulfinyl)-1,4-diacetyloxynaphthalene;
 2,3-dimethoxy-6-(pyrimidin-2-ylsulfinyl)-1,4-diacetyloxynaphthalene;
 2,3-dimethoxy-5-(pyrimidin-4-ylsulfinyl)-1,4-diacetyloxynaphthalene;
 2,3-dimethoxy-6-methylsulfinyl-1,4-diacetyloxynaphthalene;
 2,3-dimethoxy-5-benzylsulfinyl-1,4-diacetyloxynaphthalene; and
 2,3-dimethoxy-5-methoxycarbonylmethylsulfinyl-1,4-diacetyloxynaphthalene.

Example 4


2,3-Dimethoxy-5-phenylsulfonyl-1,4-diacetyloxynaphthalene.

(Preparation of Compound of Formula (I) where R³ is phenylsulfonyl).

A mixture of m-chloroperbenzoic acid (300 mg) and 2,3-dimethoxy-5-phenylthio-1,4-naphthoquinone (200 mg, 0.61 mmol) in methylene chloride (5 ml) is stirred at 22°C for 16 hours and the resulting solution then passed through an alumina column (10 g of Activity 1) eluting with chloroform. The eluates are concentrated to dryness and the residue is crystallized from isopropanol giving 95 mg of 2,3-dimethoxy-5-phenylsulfonyl-1,4-diacetyloxynaphthalene.

Example 5

The compounds of the invention prepared according to the previous Examples, and their characterizing data, are conveniently summarized in the table below:



R ₃	W	R ₂	mp
H	CH ₃	CH ₃	138—139°
	Et	CH ₃	111—112°
	n-Pr	CH ₃	53—54°
	i-Pr	CH ₃	95—96°
5-Cl	t-Bu	CH ₃	178—180°
	CH ₃	CH ₃	133—134°
	t-Bu	CH ₃	128—130°

	R ₃	W	R ₂	mp
	6-F	CH ₃	CH ₃	102—103°
5	6-Br	CH ₃	CH ₃	102—103°
	6-Cl	CH ₃	CH ₃	93—94°
10		Et	CH ₃	84—85°
		n-Pr	CH ₃	oil
		i-Pr	CH ₃	64—65°
15		t-Bu	CH ₃	132—133°
		CH ₃	Et	91—92°
20		Et	Et	81—82°
		i-Pr	Et	77—78°
	6-Cl	t-Bu	Et	104—105°
25		i-Pr	n-Pr	51—52°
		t-Bu	n-Pr	59—60°
30		CH ₃	n-Bu	74—75°
	5-CH ₃ O	CH ₃	CH ₃	69—70°
		Et	CH ₃	72—73°
35		t-Bu	CH ₃	153—154°
	6-CH ₃ O	Et	CH ₃	86—87°
40		t-BU	CH ₃	amorphous
	5-CN	CH ₃	CH ₃	152—153°
	6-CN	CH ₃	CH ₃	124—125°
45	5-NHAc	CH ₃	CH ₃	177—178°
	6-Cl	CH ₃	n-Pr	53—54°
50		Et	n-Pr	39—40°
		n-Pr	n-Pr	28—29°
		CH ₃	i-Pr	132—133°
55		Et	i-Pr	58—59°
		n-Pr	i-Pr	oil
60		i-Pr	i-Pr	oil
		t-Bu	i-Pr	oil
65	6-OCH ₃	CH ₃	CH ₃	77—78°

	R ₃	W	R ₂	mp
5	5-CH ₃	CH ₃	CH ₃	114—115°
		Et	CH ₃	
		i-Pr	CH ₃	
10		t-Bu	CH ₃	
	6-CH ₃	CH ₃	CH ₃	70—71°
		Et	CH ₃	57—58°
15		i-Pr	CH ₃	oil
		t-Bu	CH ₃	110—111°
20	5-SPh	CH ₃	CH ₃	138—140°

Example 6

Toxicity

The LD₅₀ of 6-chloro-1,4-diacetyloxy-2,3-dimethoxynaphthalene (the compound) was examined as follows:

Acute Subcutaneous Dosing

Mice were given single subcutaneous doses of up to 640 mg/kg of the compound, and observed for three weeks. No deaths occurred during this study. The subcutaneous LD₅₀ of the compound in mice was estimated to be greater than 640 mg/kg.

Acute Oral Dosing

Mice were given single oral doses of up to 1280 mg/kg of the compound, and observed for three weeks. Dose related deaths occurred in 1/12 mice dosed with 640 mg/kg, and in 4/12 mice dosed with 1280 mg/kg. The oral LD₅₀ of the compound in mice was estimated to be greater than 1280 mg/kg.

Example 7

Biological Data

As indicative of anti-psoriatic activity, the following test was carried out.

Test for Topical Anti-inflammatory Activity by Inhibition of Arachidonic Acid Induced Mouse Ear Edema


Materials and Methods

Male or female Swiss Webster mice weighing 18—27 g were randomly assigned to treatment groups of 8 or 10 animals, caged together, and given food and water ad libitum.

The test materials were prepared as solutions or suspensions in reagent grade acetone at a dose level of 100 mg/ml and arachidonic acid was prepared as a solution in acetone also at 100 mg/ml. The test materials were applied to the right ears of mice by means of an automatic microliter pipet so that 10 µl of solution was applied to each of the inner and outer surfaces. Each ear therefore received a total of 20 µl of solution containing 2 mg of test material. One hour after application of the test material, the arachidonic acid solution was applied in the same manner. One hour after the arachidonic acid application the animals were sacrificed by cervical dislocation and the right ears were removed. An 8 mm disc was punched from each ear with a biopsy punch, and the discs were weighed to the nearest 0.1 mg. For the purpose of determining the anti-inflammatory effect of test materials a negative control group receiving two applications of acetone only, and a positive control group receiving acetone alone followed by arachidonic acid were run in each experiment. The percent inhibition resulting from treatment with the test material was calculated as follows:

$$\% \text{ Inhib.} = \frac{\text{Plug wt. (Pos. Control)} - \text{Plug wt. (Treated)}}{\text{Plug wt. (Pos. Control)} - \text{Plug wt. (Neg. control)}} \times 100$$


TABLE
Inhibition of Arachidonic Acid Induced Mouse Ear Inflammation



	R	R ₂	X	Y	% Edema Inhibition
15	COCH ₃	CH ₃	Cl	H	51
	COCH ₂ CH ₃	CH ₃	Cl	H	49
20	COCH(CH ₃) ₂	CH ₃	Cl	H	23
	COCH ₃	CH ₂ CH ₃	Cl	H	38
25	COCH ₂ CH ₃	CH ₂ CH ₃	Cl	H	50
	COC(CH ₃) ₃	CH ₂ CH ₃	Cl	H	19
	COCH(CH ₃) ₂	CH ₂ CH ₂ CH ₃	Cl	H	28
30	COCH ₃	CH ₂ CH ₂ CH ₂ CH ₃	Cl	H	23
	COCH ₃	CH ₃	H	H	19
35	COCH ₂ CH ₃	CH ₃	H	H	33
	COCH ₂ CH ₂ CH ₂ CH ₃	CH ₃	H	H	59
	COCH(CH ₃) ₂	CH ₃	H	H	53
40	COCH ₃	CH ₃	F	H	40
	COCH ₃	CH ₃	Br	H	42
45	COCH ₂ CH ₃	CH ₃	OCH ₃	H	49
	COCH ₃	CH ₃	H	OCH ₃	47
	COCH ₂ CH ₃	CH ₃	H	OCH ₃	57
50	COCH ₃	CH ₃	H	CN	24


Claims for the Contracting States: BE CH DE FR GB IT LI LU NL SE

1. A composition in a form suitable for topical administration for relieving the condition of psoriasis which comprises a pharmaceutically acceptable, non-toxic carrier and a psoriasis relieving amount of a compound of the formula



Results


TABLE
Inhibition of Arachidonic Acid Induced Mouse Ear Inflammation



	R	R ₂	X	Y	% Edema Inhibition
15	COCH ₃	CH ₃	Cl	H	51
	COCH ₂ CH ₃	CH ₃	Cl	H	49
20	COCH(CH ₃) ₂	CH ₃	Cl	H	23
	COCH ₃	CH ₂ CH ₃	Cl	H	38
25	COCH ₂ CH ₃	CH ₂ CH ₃	Cl	H	50
	COC(CH ₃) ₃	CH ₂ CH ₃	Cl	H	19
	COCH(CH ₃) ₂	CH ₂ CH ₂ CH ₃	Cl	H	28
30	COCH ₃	CH ₂ CH ₂ CH ₂ CH ₃	Cl	H	23
	COCH ₃	CH ₃	H	H	19
35	COCH ₂ CH ₃	CH ₃	H	H	33
	COCH ₂ CH ₂ CH ₂ CH ₃	CH ₃	H	H	59
	COCH(CH ₃) ₂	CH ₃	H	H	53
40	COCH ₃	CH ₃	F	H	40
	COCH ₃	CH ₃	Br	H	42
45	COCH ₂ CH ₃	CH ₃	OCH ₃	H	49
	COCH ₃	CH ₃	H	OCH ₃	47
	COCH ₂ CH ₃	CH ₃	H	OCH ₃	57
50	COCH ₃	CH ₃	H	CN	24

Claims for the Contracting States: BE CH DE FR GB IT LI LU NL SE

1. A composition in a form suitable for topical administration for relieving the condition of psoriasis which comprises a pharmaceutically acceptable, non-toxic carrier and a psoriasis relieving amount of a compound of the formula




wherein:

R^1 and R^2 are lower alkoxy of one to six carbon atoms or lower alkylthio of one to six carbon atoms;

R^3 is hydrogen, lower alkyl of one to six carbon atoms, lower alkoxy of one to six carbon atoms, optionally substituted phenyl, optionally substituted phenyl lower alkyl, optionally substituted phenyl lower alkoxy, amino, lower alkylamino, lower dialkylamino, halo, cyano, or $S(O)_nR$ wherein R is lower alkyl of one to six carbon atoms; optionally substituted phenyl; optionally substituted phenyl lower alkyl; or heterocyclic aryl of three to nine ring atoms containing one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur wherein the heterocyclic aryl is optionally substituted by one or more substituents selected from the group consisting of lower alkyl, lower alkoxy, halo and cyano and the pharmaceutically acceptable acid addition salts thereof; and n is 0, 1 or 2; and

W is alkyl of one to seven carbon atoms.

2. The composition according to Claim 1 wherein the compound is



wherein R^1 , R^2 , R^3 , and W are as defined in Claim 1.

3. The composition according to Claim 2 wherein R^1 and R^2 are lower alkoxy of one to six carbon atoms.

4. The composition according to Claim 3 wherein R^3 is selected from the group consisting of hydrogen, halo, cyano, and alkoxy of one to four carbon atoms.

5. The composition according to Claim 4 wherein R^3 is selected from the group consisting of hydrogen, fluoro, chloro and bromo.

6. The composition according to Claim 4 wherein R^3 is cyano.

7. The composition according to Claim 5 wherein the compound is 2,3-dimethoxy-1,4-acetyloxy-naphthalene.


8. The composition according to Claim 5 wherein the compound is 6-bromo-2,3-dimethoxy-1,4-acetyloxynaphthalene.

9. The composition of Claim 5 wherein the compound is 6-chloro-2,3-dimethoxy-1,4-acetyloxy-naphthalene.

10. A composition of Claim 5 wherein the compound is 6-chloro-2,3-di-n-butoxy-1,4-acetyloxy-naphthalene.

11. The composition according to Claim 2 wherein R^1 and R^2 are lower alkylthio of one to six carbon atoms.

12. A compound of the formula



wherein:


R^1 and R^2 are lower alkoxy of one to six carbon atoms or lower alkylthio of one to six carbon atoms;

R^3 is hydrogen, lower alkyl of one to six carbon atoms, lower alkoxy of one to six carbon atoms, optionally substituted phenyl, optionally substituted phenyl lower alkyl, optionally substituted phenyl lower alkoxy, amino, lower alkylamino, lower dialkylamino, halo, cyano, or $S(O)_nR$ wherein R is alkyl of one to six carbon atoms; optionally substituted phenyl; optionally substituted phenyl lower alkyl; or heterocyclic aryl of three to nine ring atoms containing one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur wherein the heterocyclic aryl is optionally substituted by one or more substituents selected from the group consisting of lower alkyl, lower alkoxy, halo and cyano and the pharmaceutically acceptable acid addition salts thereof; and n is 0, 1 or 2; and

W is alkyl of one to seven carbon atoms; for use in treating psoriasis in mammals.



13. A compound of the formula




wherein:

R¹ and R² are lower alkoxy of one to six carbon atoms or lower alkylthio of one to six carbon atoms;
 R³ is hydrogen, lower alkyl of one to six carbon atoms, lower alkoxy of one to six carbon atoms, optionally substituted phenyl, optionally substituted phenyl lower alkyl, optionally substituted phenyl lower alkoxy, amino, lower alkylamino, lower dialkylamino, halo, cyano, or S(O)_nR wherein R is lower alkyl of one to six carbon atoms; optionally substituted phenyl; optionally substituted phenyl lower alkyl; or heterocyclic aryl of three to nine ring atoms containing one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur wherein the heterocyclic aryl is optionally substituted by one or more substituents selected from the group consisting of lower alkyl, lower alkoxy, halo and cyano and the pharmaceutically acceptable acid addition salts thereof; and n is 0, 1 or 2; and

W is alkyl of one to seven carbon atoms; with the proviso that R³ is not hydrogen when R¹ and R² are methoxy and W is methyl.

14. A compound of Claim 13 of the formula



wherein R¹, R², R³ and W are as defined in Claim 13.

15. A compound of Claim 14 wherein R¹ and R² are lower alkoxy of one to six carbon atoms.

16. A compound of Claim 15 wherein R³ is selected from the group consisting of fluoro, chloro and bromo.


17. A compound of Claim 15 wherein R³ is cyano.

18. A compound of Claim 16 which is 6-chloro-2,3-dimethoxy-1,4-acetyloxynaphthalene.

19. A compound of Claim 16 which is 6-chloro-2,3-di-n-butoxy-1,4-acetyloxynaphthalene.

20. A compound of Claim 14 wherein R¹ and R² are lower alkylthio of one to six carbon atoms.

21. A process for preparing a compound of the formula




wherein:

R¹ and R² are lower alkoxy of one to six carbon atoms or lower alkylthio of one to six carbon atoms;

R³ is hydrogen, lower alkyl of one to six carbon atoms, lower alkoxy of one to six carbon atoms, optionally substituted phenyl, optionally substituted phenyl lower alkyl, optionally substituted phenyl lower alkoxy, amino, lower alkylamino, lower dialkylamino, halo, cyano, or S(O)_nR wherein R is lower alkyl of one to six carbon atoms; optionally substituted phenyl; optionally substituted phenyl lower alkyl; or heterocyclic aryl of three to nine ring atoms containing one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur wherein the heterocyclic aryl is optionally substituted by one or more substituents selected from the group consisting of lower alkyl, lower alkoxy, halo and cyano and the pharmaceutically acceptable acid addition salts thereof; and n is 0, 1 or 2; and

W is alkyl of one to seven carbon atoms; with the proviso that R³ is not hydrogen when R¹ and R² are methoxy and W is methyl which comprises acylating a compound of the formula






(XI)

wherein R^1 , R^2 and R^3 are as defined above.

22. A process according to Claim 21, involving as a starting material a compound of formula (VI):




(VI)

wherein R^1 , R^2 and R^3 are as defined in claim 21; which starting material is converted to a compound of formula (XI).

23. A process for preparing a composition according to Claim 1, which comprises mixing together the compound of formula (I) with the pharmaceutically acceptable, non-toxic carrier.

24. As a novel intermediate, a compound of formula (XI):




(XI)

wherein R^1 , R^2 and R^3 are as defined in Claim 13.

Claims for the Contracting State: AT

1. A process for preparing a compound of the formula



(I)


wherein:

R^1 and R^2 are lower alkoxy of one to six carbon atoms or lower alkylthio of one to six carbon atoms;
 R^3 is hydrogen, lower alkyl of one to six carbon atoms, lower alkoxy of one to six carbon atoms, optionally substituted phenyl, optionally substituted phenyl lower alkyl, optionally substituted phenyl lower alkoxy, amino, lower alkylamino, lower dialkylamino, halo, cyano, or $S(O)_nR$ wherein R is lower alkyl of one to six carbon atoms; optionally substituted phenyl; optionally substituted phenyl lower alkyl; or heterocyclic aryl of three to nine ring atoms containing one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur wherein the heterocyclic aryl is optionally substituted by one or more substituents selected from the group consisting of lower alkyl, lower alkoxy, halo and cyano and the pharmaceutically acceptable acid addition salts thereof; and n is 0, 1 or 2; and

W is alkyl of one to seven carbon atoms; with the proviso that R^3 is not hydrogen when R^1 and R^2 are methoxy and W is methyl;

which comprises acylating a compound of the formula






(XI)

10 wherein R^1 , R^2 and R^3 are as defined above.

2. A process according to Claim 1 for the preparation of a compound of the formula (I)



(I)

wherein R^1 , R^2 , R^3 and W are as defined in Claim 1.

3. A process according to Claim 2 wherein R^1 and R^2 are lower alkoxy of one to six carbon atoms.

4. A process according to Claim 3 wherein R^3 is selected from fluoro, chloro, and bromo.


5. A process according to Claim 3 wherein R^3 is cyano.

6. A process according to Claim 4 for the preparation of 6-chloro-2,3-dimethoxy-1,3-acetyloxynaphthalene.

7. A process according to Claim 4 for the preparation of 6-chloro-2,3-di-n-butoxy-1,4-acetyloxynaphthalene.

8. A process according to Claim 2 wherein R^1 and R^2 are lower alkylthio of one to six carbon atoms.


9. A process according to any of the Claims 1 to 8 involving as a starting material a compound of formula (VI):



(VI)

wherein R^1 , R^2 and R^3 are as defined; which starting material is converted to a compound of formula (XI).

10. A process for preparing a composition in a form suitable for topical administration for relieving the condition of psoriasis which composition comprises a pharmaceutically acceptable, non-toxic carrier and a psoriasis relieving amount of a compound of the formula



(I)

wherein:


R^1 and R^2 are lower alkoxy of one to six carbon atoms or lower alkylthio of one to six carbon atoms;

R^3 is hydrogen, lower alkyl of one to six carbon atoms, lower alkoxy of one to six carbon atoms, optionally substituted phenyl, optionally substituted phenyl lower alkyl, optionally substituted phenyl lower alkoxy, amino, lower alkylamino, lower dialkylamino, halo, cyano, or $S(O)_nR$ wherein R is lower alkyl of one to six carbon atoms; optionally substituted phenyl; optionally substituted phenyl lower alkyl; or heterocyclic aryl of three to nine ring atoms containing one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur wherein the heterocyclic aryl is optionally substituted by one or more substituents selected from the group consisting of lower alkyl, lower alkoxy, halo and cyano and the pharmaceutically acceptable acid addition salts thereof; and n is 0, 1 or 2; and

W is alkyl of one to seven carbon atoms; which process comprises mixing together the compound of formula (I) with the pharmaceutically acceptable, non-toxic carrier.




1. Eine Zusammensetzung in einer zur topischen Verabreichung geeigneten Form zur Linderung der Psoriasis, die enthält: einen pharmazeutisch annehmbaren nicht-toxischen Träger und eine die Psoriasis lindernde Menge einer Verbindung der Formel



15 worin

R¹ und R² Niederalkoxy mit 1 bis 6 Kohlenstoffatomen oder Niederalkylthio mit 1 bis 6 Kohlenstoffatomen sind; R³ ist Wasserstoff, Niederalkyl mit 1 bis 6 Kohlenstoffatomen, Niederalkoxy mit 1 bis 6 Kohlenstoffatomen, gegebenenfalls substituiertes Phenyl, gegebenenfalls substituiertes Phenylniederalkyl, gegebenenfalls substituiertes Phenylniederalkoxy, Amino, Niederalkylamino, Diniederalkylamino, Halogen, Cyano oder S(O)_nR, worin R niederalkyl mit 1 bis 6 Kohlenstoffatomen, gegebenenfalls substituiertes Phenyl, gegebenenfalls substituiertes Phenylniederalkyl oder heterocyclisches Aryl mit 3 bis 9 Ringatomen, welches 1 oder 2 Heteroatome aus der Gruppe von Stickstoff, Sauerstoff und Schwefel enthält, wobei das heterocyclische Aryl gegebenenfalls durch einen oder mehrere Substituenten, ausgewählt aus Niederalkyl, Niederalkoxy, Halogen und Cyano, substituiert ist, und die pharmazeutisch annehmbaren Säureadditionssalze desselben bedeutet; und n 0, 1 oder 2 ist; und W Alkyl mit 1 bis 7 Kohlenstoffatomen darstellt.

2. Zusammensetzung nach Anspruch 1, worin die Verbindung



ist, worin R¹, R², R³ und W wie in Anspruch 1 definiert sind.

3. Zusammensetzung nach Anspruch 2, worin R¹ und R² Niederalkoxy mit 1 bis 6 Kohlenstoffatomen sind.

4. Zusammensetzung nach Anspruch 3, worin R³ ausgewählt ist aus Wasserstoff, Halogen, Cyano und Alkoxy mit 1 bis 4 Kohlenstoffatomen.

5. Zusammensetzung nach Anspruch 4, worin R³ ausgewählt ist aus Wasserstoff, Fluor, Chlor und Brom.

6. Zusammensetzung nach Anspruch 4, worin R³ Cyano ist.

7. Zusammensetzung nach Anspruch 5, worin die Verbindung 2,3-Dimethoxy-1,4-acetyloxynaphthalin ist.


8. Zusammensetzung nach Anspruch 5, worin die Verbindung 6-Brom-2,3-dimethoxy-1,4-acetyloxynaphthalin ist.

9. Zusammensetzung nach Anspruch 5, worin die Verbindung 6-Chlor-2,3-dimethoxy-1,4-acetyloxynaphthalin ist.

10. Zusammensetzung nach Anspruch 5, worin die Verbindung 6-Chlor-2,3-di-n-butoxy-1,4-acetyloxynaphthalin ist.

11. Zusammensetzung nach Anspruch 2, worin R¹ und R² Niederalkylthio mit 1 bis 6 Kohlenstoffatomen sind.


12. Eine Verbindung der Formel



worin

R^1 und R^2 Niederalkoxy mit 1 bis 6 Kohlenstoffatomen oder Niederalkylthio mit 1 bis 6 Kohlenstoffatomen sind; R^3 ist Wasserstoff, Niederalkyl mit 1 bis 6 Kohlenstoffatomen, Niederalkoxy mit 1 bis 6 Kohlenstoffatomen, gegebenenfalls substituiertes Phenyl, gegebenenfalls substituiertes Phenylniederalkyl, gegebenenfalls substituiertes Phenylniederalkoxy, Amino, Niederalkylamino, Diniederalkylamino, Halogen, Cyano oder $S(O)_nR$, worin R Alkyl mit 1 bis 6 Kohlenstoffatomen, gegebenenfalls substituiertes Phenyl, gegebenenfalls substituiertes Phenylniederalkyl oder heterocyclisches Aryl mit 3 bis 9 Ringatomen, welches 1 oder 2 Heteroatome aus der Gruppe von Stickstoff, Sauerstoff und Schwefel enthält, wobei das heterocyclische Aryl gegebenenfalls durch einen oder mehrere Substituenten, ausgewählt aus Niederalkyl, Niederalkoxy, Halogen und Cyano, substituiert ist, und die pharmazeutisch annehmbaren Säureadditionssalze desselben bedeutet; und n 0, 1 oder 2 ist; und W Alkyl mit 1 bis 7 Kohlenstoffatomen darstellt, zur Verwendung bei der Behandlung der Psoriasis bei Mensch und Säugetier.


13. Eine Verbindung der Formel



worin

R^1 und R^2 Niederalkoxy mit 1 bis 6 Kohlenstoffatomen oder Niederalkylthio mit 1 bis 6 Kohlenstoffatomen sind; R^3 ist Wasserstoff, Niederalkyl mit 1 bis 6 Kohlenstoffatomen, Niederalkoxy mit 1 bis 6 Kohlenstoffatomen, gegebenenfalls substituiertes Phenyl, gegebenenfalls substituiertes Phenylniederalkyl, gegebenenfalls substituiertes Phenylniederalkoxy, Amino, Niederalkylamino, Diniederalkylamino, Halogen, Cyano oder $S(O)_nR$, worin R Niederalkyl mit 1 bis 6 Kohlenstoffatomen, gegebenenfalls substituiertes Phenyl, gegebenenfalls substituiertes Phenylniederalkyl oder heterocyclisches Aryl mit 3 bis 9 Ringatomen, welches 1 oder 2 Heteroatome aus der Gruppe von Stickstoff, Sauerstoff und Schwefel enthält, wobei das heterocyclische Aryl gegebenenfalls durch einen oder mehrere Substituenten, ausgewählt aus Niederalkyl, Niederalkoxy, Halogen und Cyano, substituiert ist, und die pharmazeutisch annehmbaren Säureadditionssalze desselben bedeutet; und n 0, 1 oder 2 ist; und W Alkyl mit 1 bis 7 Kohlenstoffatomen darstellt, mit der Bedingung, daß R^3 nicht Wasserstoff ist, wenn R^1 und R^2 Methoxy bedeuten und W Methyl ist.

14. Eine Verbindung nach Anspruch 13 mit der Formel



worin R^1 , R^2 , R^3 und W wie in Anspruch 13 definiert sind.

15. Eine Verbindung nach Anspruch 14, worin R^1 und R^2 Niederalkoxy mit 1 bis 6 Kohlenstoffatomen sind.

16. Eine Verbindung nach Anspruch 15, worin R^3 ausgewählt ist aus Fluor, Chlor und Brom.


17. Eine Verbindung nach Anspruch 15, worin R^3 Cyano ist.

18. Eine Verbindung nach Anspruch 16, nämlich 6-Chlor-2,3-dimethoxy-1,4-acetyloxynaphthalin.

19. Eine Verbindung nach Anspruch 16, nämlich 6-Chlor-2,3-di-n-butoxy-1,4-acetyloxynaphthalin.


20. Eine Verbindung nach Anspruch 14, worin R^1 und R^2 Niederalkylthio mit 1 bis 6 Kohlenstoffatomen sind.

21. Verfahren zur Herstellung einer Verbindung der Formel




worin

R¹ und R² Niederalkoxy mit 1 bis 6 Kohlenstoffatomen oder Niederalkylthio mit 1 bis 6 Kohlenstoffatomen sind; R³ ist Wasserstoff, Niederalkyl mit 1 bis 6 Kohlenstoffatomen Niederalkoxy mit 1 bis 6 Kohlenstoffatomen, gegebenenfalls substituiertes Phenyl niederalkyl, gegebenenfalls substituiertes Phenylniederalkyl, gegebenenfalls substituiertes Phenylniederalkyloxy, Amino, Niederalkylamino, Diniederalkylamino, Halogen, Cyano oder S(O)_nR, worin R Niederalkyl mit 1 bis 6 Kohlenstoffatomen, gegebenenfalls substituiertes Phenyl, gegebenenfalls substituiertes Phenylniederalkyl oder heterocyclisches Aryl mit 3 bis 9 Ringatomen, welches 1 oder 2 Heteroatome aus der Gruppe von Stickstoff, Sauerstoff und Schwefel enthält, wobei das heterocyclische Aryl gegebenenfalls durch einen oder mehrere Substituenten, ausgewählt aus Niederalkyl, Niederalkoxy, Halogen und Cyano, substituiert ist, und die pharmazeutisch annehmbaren Säureadditionssalze desselben bedeutet; und n 0, 1 oder 2 ist; und W Alkyl mit 1 bis 7 Kohlenstoffatomen darstellt, mit der Bedingung, daß R³ nicht Wasserstoff ist, wenn R¹ und R² Methoxy sind und W Methyl ist, dadurch gekennzeichnet, daß man eine Verbindung der Formel



worin R¹, R² und R³ wie oben definiert sind, acyliert.


22. Verfahren nach Anspruch 21 unter Verwendung einer Verbindung der Formel (VI)



worin R¹, R² und R³ wie in Anspruch 21 definiert sind, als Ausgangsmaterial, das in eine Verbindung der Formel (XI) umgewandelt wird.

23. Verfahren zur Herstellung eine Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet, daß man die Verbindung der Formel (I) mit dem pharmazeutisch annehmbaren nicht-toxischen Träger zusammen mischt.


24. Eine Verbindung der Formel (XI)



worin R¹, R² und R³ wie in Anspruch 13 definiert sind, als neues Zwischenprodukt.

Patentansprüche für den Vertragsstaat: AT


1. Verfahren zur Herstellung einer Verbindung der Formel



worin




R¹ und R² Niederalkoxy mit 1 bis 6 Kohlenstoffatomen oder Niederalkylthio mit 1 bis 6 Kohlenstoffatomen sind; R³ ist Wasserstoff, Niederalkyl mit 1 bis 6 Kohlenstoffatomen, Niederalkoxy mit 1 bis 6 Kohlenstoffatomen, gegebenenfalls substituiertes Phenyl, gegebenenfalls substituiertes Phenylniederalkyl, gegebenenfalls substituiertes Phenylniederalkoxy, Amino, Niederalkylamino, Diniederalkylamino, Halogen, Cyano oder S(O)_nR, worin R Niederalkyl mit 1 bis 6 Kohlenstoffatomen, gegebenenfalls substituiertes Phenyl, gegebenenfalls substituiertes Phenylniederalkyl oder heterocyclisches Aryl mit 3 bis 9 Ringatomen, welches 1 oder 2 Heteroatome aus der Gruppe von Stickstoff, Sauerstoff und Schwefel enthält, wobei das heterocyclische Aryl gegebenenfalls durch einen oder mehrere Substituenten, ausgewählt aus Niederalkyl, Niederalkoxy, Halogen und Cyano, substituiert ist, und die pharmazeutisch annehmbaren Säureadditionssalze desselben bedeutet; und n 0, 1 oder 2 ist; und W Alkyl mit 1 bis 7 Kohlenstoffatomen darstellt, mit der Bedingung, daß R³ nicht Wasserstoff ist, wenn R¹ und R² Methoxy sind und W Methyl ist, dadurch gekennzeichnet, daß man eine Verbindung der Formel



worin R¹, R² und R³ wie oben definiert sind, acyliert.

2. Verfahren nach Anspruch 1 zur Herstellung einer Verbindung der Formel (I)'



worin R¹, R², R³ und W wie in Anspruch 1 definiert sind.

3. Verfahren nach Anspruch 2, worin R¹ und R² Niederalkoxy mit 1 bis 6 Kohlenstoffatomen sind.

4. Verfahren nach Anspruch 3, worin R³ aus Fluor, Chlor und Brom ausgewählt ist.


5. Verfahren nach Anspruch 3, worin R³ Cyano ist.

6. Verfahren nach Anspruch 4 zur Herstellung von 6-Chlor-2,3-dimethoxy-1,4-acetyloxynaphthalin.

7. Verfahren nach Anspruch 4 zur Herstellung von 6-Chlor-2,3-di-n-butoxy-1,4-acetyloxynaphthalin.

8. Verfahren nach Anspruch 2, worin R¹ und R² Niederalkylthio mit 1 bis 6 Kohlenstoffatomen sind.

9. Verfahren nach einem der Ansprüche 1 bis 8 unter Verwendung einer Verbindung der Formel (VI)




worin R¹, R² und R³ wie oben definiert sind, als Ausgangsmaterial, das in eine Verbindung der Formel (XI) umgewandelt wird.

10. Verfahren zur Herstellung einer Zusammensetzung in einer zur topischen Verabreichung zur Linderung der Psoriasis geeigneten Form, die umfaßt:

einen pharmazeutisch annehmbaren nicht-toxischen Träger und eine die Psoriasis lindernde Menge einen Verbindung der Formel






5 worin

10 R^1 und R^2 Niederalkoxy mit 1 bis 6 Kohlenstoffatomen oder Niederalkylthio mit 1 bis 6 Kohlenstoffatomen sind; R^3 ist Wasserstoff, Niederalkyl mit 1 bis 6 Kohlenstoffatomen, Niederalkoxy mit 1 bis 6 Kohlenstoffatomen, gegebenenfalls substituiertes Phenyl, gegebenenfalls substituiertes Phenylniederalkyl, gegebenenfalls substituiertes Phenylniederalkoxy, Amino, Niederalkylamino, Diniederalkylamino, Halogen, Cyano oder $S(O)_nR$, worin R Niederalkyl mit 1 bis 6 Kohlenstoffatomen, gegebenfalls substituiertes Phenyl, gegebenfalls substituiertes Phenylniederalkyl oder heterocyclisches Aryl mit 3 bis 9 Ringatomen, welches 1 oder 2 heteroatome aus der Gruppe von Stickstoff, Sauerstoff und Schwefel enthält, wobei das heterocyclische Aryl gegebenenfalls durch einen oder mehrere Substituenten, ausgewählt aus Niederalkyl, Niederalkoxy, Halogen und Cyano, substituiert ist, und die pharmazeutisch annehmbaren Säureadditionssalze desselben bedeutet; und n 0, 1 oder 2 ist; und W Alkyl mit 1 bis 7 Kohlenstoffatomen darstellt;

20 dadurch gekennzeichnet, daß man die Verbindung der Formel (I) mit dem pharmazeutisch annehmbaren nicht-toxischen Träger mischt.

25 **Revendications pour les Etats contractants: BE CH DE FR GB IT LI LU NL SE**

1. Composition sous une forme qui convient à l'administration topique pour soulager l'état de psoriasis, qui comprend un support non toxique pharmaceutiquement acceptable et une quantité atténuant le psoriasis d'un composé de formule




35 dans laquelle:

40 R^1 et R^2 sont des groupes alkoxy inférieurs ayant 1 à 6 atomes de carbone ou des groupes alkylthio inférieurs ayant 1 à 6 atomes de carbone;

R^3 représente l'hydrogène, un groupe alkyle inférieur ayant 1 à 6 atomes de carbone, un groupe alkoxy inférieur ayant 1 à 6 atomes de carbone, un groupe phényle éventuellement substitué, un groupe phényl-(alkyle inférieur) éventuellement substitué, un groupe phényl-(alkoxy inférieur) éventuellement substitué, un groupe amino, alkylamino inférieur, di(alkyle inférieur)amino, halogéno, cyano ou $S(O)_nR$ où R est un radical alkyle inférieur ayant 1 à 6 atomes de carbone; un groupe phényle éventuellement substitué; un groupe phényl-(alkyle inférieur) éventuellement substitué; ou un groupe aryle hétérocyclique de 3 à 9 atomes dans le noyau contenant un ou deux hétéroatomes choisis entre des atomes d'azote, d'oxygène et de soufre, le groupe aryle hétérocyclique étant éventuellement substitué par un ou plusieurs substituants choisis entre des substituants alkyle inférieur, alkoxy inférieur, halogéno et cyano, et leurs sels d'addition d'acides pharmaceutiquement acceptables; et n a la valeur 0, 1 ou 2; et

50 W est un groupe alkyle ayant 1 à 7 atomes de carbone.

2. Composition suivant la revendication 1, dans laquelle le composé répond à la formule:



55 où R^1 , R^2 , R^3 et W sont tels que définis dans la revendication 1.

3. Composition suivant la revendication 2, dans laquelle R^1 et R^2 sont des groupes alkoxy inférieurs 65 ayant 1 à 6 atomes de carbone.



34

4. Composition suivant la revendication 3, dans laquelle R^3 est choisi entre l'hydrogène, un radical halogéno, un radical cyano et un radical alkoxy ayant 1 à 4 atomes de carbone.

5. Composition suivant la revendication 4, dans laquelle R^3 est choisi entre l'hydrogène et les radicaux fluoro, chloro et bromo.

6. Composition suivant la revendication 4, dans laquelle R^3 est un groupe cyano.

7. Composition suivant la revendication 5, dans laquelle le composé est le 2,3-diméthoxy-1,4-acétyloxynaphtalène.


8. Composition suivant la revendication 5, dans laquelle le composé est le 6-bromo-2,3-diméthoxy-1,4-acétyloxynaphtalène.

9. Composition suivant la revendication 5, dans laquelle le composé est le 6-chloro-2,3-diméthoxy-1,4-acétyloxynaphtalène.

10. Composition suivant la revendication 5, dans laquelle le composé est le 6-chloro-2,3-di-n-butoxy-1,4-acétyloxynaphtalène.

11. Composition suivant la revendication 2, dans laquelle R^1 et R^2 sont des groupes alkylthio inférieurs ayant 1 à 6 atomes de carbone.

12. Composé de formule




dans laquelle:

R^1 et R^2 sont des groupes alkoxy inférieurs ayant 1 à 6 atomes de carbone ou des groupes alkylthio inférieurs ayant 1 à 6 atomes de carbone;

R^3 représente l'hydrogène, un groupe alkyle inférieur ayant 1 à 6 atomes de carbone, un groupe alkoxy inférieur ayant 1 à 6 atomes de carbone, un groupe phényle éventuellement substitué, un groupe phényl-(alkyle inférieur) éventuellement substitué, un groupe phényl-(alkoxy inférieur) éventuellement substitué, un groupe amino, alkylamino inférieur, di(alkyle inférieur)amino, halogéno, cyano ou $S(O)_nR$ où R est un radical alkyle inférieur ayant 1 à 6 atomes de carbone; un groupe phényle éventuellement substitué; un groupe phényl-(alkyle inférieur) éventuellement substitué; ou un groupe aryle hétérocyclique de 3 à 9 atomes dans le noyau contenant un ou deux hétéroatomes choisis entre des atomes d'azote, d'oxygène et de soufre, le groupe aryle hétérocyclique étant éventuellement substitué par un ou plusieurs substituants choisis entre des substituants alkyle inférieur, alkoxy inférieur, halogéno et cyano, et leurs sels d'addition d'acides pharmaceutiquement acceptables; et n a la valeur 0, 1 ou 2; et

W est un groupe alkyle ayant 1 à 7 atomes de carbone; destiné à être utilisé dans le traitement du psoriasis chez des mammifères.

13. Composé de formule



dans laquelle:

R^1 et R^2 sont des groupes alkoxy inférieurs ayant 1 à 6 atomes de carbone ou des groupes alkylthio inférieurs ayant 1 à 6 atomes de carbone;


R^3 représente l'hydrogène, un groupe alkyle inférieur ayant 1 à 6 atomes de carbone, un groupe alkoxy inférieur ayant 1 à 6 atomes de carbone, un groupe phényle éventuellement substitué, un groupe phényl-(alkyle inférieur) éventuellement substitué, un groupe phényl-(alkoxy inférieur) éventuellement substitué, un groupe amino, alkylamino inférieur, di(alkyle inférieur)amino, halogéno, cyano ou $S(O)_nR$ où R est un radical alkyle inférieur ayant 1 à 6 atomes de carbone; un groupe phényle éventuellement substitué; un groupe phényl-(alkyle inférieur) éventuellement substitué; ou un groupe aryle hétérocyclique de 3 à 9 atomes dans le noyau contenant un ou deux hétéroatomes choisis entre des atomes d'azote, d'oxygène et de soufre, le groupe aryle hétérocyclique étant éventuellement substitué par un ou plusieurs substituants choisis entre des substituants alkyle inférieur, alkoxy inférieur, halogéno et cyano, et leurs sels d'addition d'acides pharmaceutiquement acceptables; et n a la valeur 0, 1 ou 2; et

W est un groupe alkyle ayant 1 à 7 atomes de carbone; sous réserve que R^3 ne soit pas l'hydrogène



lorsque R¹ et R² sont des groupes méthoxy et W est un groupe méthyle.

14. Composé suivant la revendication 13, de formule



dans laquelle R¹, R², R³ et W sont tels que définis dans la revendication 13.

15. Composé suivant la revendication 14, dans lequel R¹ et R² sont des groupes alkoxy inférieurs ayant 1 à 6 atomes de carbone.

16. Composé suivant la revendication 15, dans lequel R³ est choisi entre les radicaux fluoro, chloro et bromo.


17. Composé suivant la revendication 15 dans lequel R³ est le radical cyano.

18. Composé suivant la revendication 16, qui est le 6-chloro-2,3-diméthoxy-1,4-acétyloxynaphtalène.

19. Composé suivant la revendication 16, qui est le 6-chloro-2,3-di-n-butoxy-1,4-acétyloxynaphtalène.

20. Composé suivant la revendication 14, dans lequel R¹ et R² sont des groupes alkylthio inférieurs ayant 1 à 6 atomes de carbone.

21. Procédé de préparation d'un composé de formule




dans laquelle

35 R¹ et R² sont des groupes alkoxy inférieurs ayant 1 à 6 atomes de carbone ou des groupes alkylthio inférieurs ayant 1 à 6 atomes de carbone;

R³ représente l'hydrogène, un groupe alkyle inférieur ayant 1 à 6 atomes de carbone, un groupe alkoxy inférieur ayant 1 à 6 atomes carbone, un groupe phényle éventuellement substitué, un groupe phényl-(alkyle inférieur) éventuellement substitué, un groupe phényl-(alkoxy inférieur) éventuellement substitué, un groupe amino, alkylamino inférieur, di(alkyle inférieur)amino, halogéno, cyano ou S(O)_nR où R est un radical alkyle inférieur ayant 1 à 6 atomes de carbone; un groupe phényle éventuellement substitué; un groupe phényl-(alkyle inférieur) éventuellement substitué; ou un groupe aryle hétérocyclique de 3 à 9 atomes dans le noyau contenant un ou deux hétéroatomes choisis entre des atomes d'azote, d'oxygène et de soufre, le groupe aryle hétérocyclique étant éventuellement substitué par un ou plusieurs substituants choisis entre des substituants alkyle inférieur, alkoxy inférieur, halogéno et cyano, et leurs sels d'addition d'acides pharmaceutiquement acceptables; et n a la valeur 0, 1 ou 2; et


45 W est un groupe alkyle ayant 1 à 7 atomes de carbone; sous réserve que R³ ne soit pas l'hydrogène lorsque R¹ et R² sont des groupe méthoxy et W est un groupe méthyle, qui consiste à acyler un composé de formule



dans laquelle R¹, R² et R³ sont tels que définis ci-dessus.

60 22. Procédé suivant la revendication 21, impliquant comme matière de départ un composé de formule (VI):






(VI)

10 dans laquelle R^1 , R^2 et R^3 sont tels que définis dans la revendication 21; cette matière de départ étant convertie en un composé de formule (XI).

23. Procédé de préparation d'une composition suivant la revendication 1, qui consiste à mélanger ensemble le composé de formule (I) avec le support non toxique pharmaceutiquement acceptable.

24. A titre de composé intermédiaire nouveau, un composé de formule (XI):




(XI)

25 dans laquelle R^1 , R^2 et R^3 sont tels que définis dans la revendication 13.

Revendications pour l'Etat contractant: AT

1. Procédé de préparation d'un composé de formule



(I)


dans laquelle:

R^1 et R^2 sont des groupes alkoxy inférieurs ayant 1 à 6 atomes de carbone ou des groupes alkylthio inférieurs ayant 1 à 6 atomes de carbone;

R^3 représente l'hydrogène, un groupe alkyle inférieur ayant 1 à 6 atomes de carbone, un groupe alkoxy inférieur ayant 1 à 6 atomes de carbone, un groupe phényle éventuellement substitué, un groupe phényl-(alkyle inférieur) éventuellement substitué, un groupe phényl-(alkoxy inférieur) éventuellement substitué, un groupe amino, alkylamino inférieur, di(alkyle inférieur)amino, halogéno, cyano ou $S(O)_nR$ où R est un radical alkyle inférieur ayant 1 à 6 atomes de carbone; un groupe phényle éventuellement substitué; un groupe phényl-(alkyle inférieur) éventuellement substitué; ou un groupe aryle hétérocyclique de 3 à 9 atomes dans le noyau contenant un ou deux hétéroatomes choisis entre des atomes d'azote, d'oxygène et de soufre, le groupe aryle hétérocyclique étant éventuellement substitué par un ou plusieurs substituants choisis entre des substituants alkyle inférieur, alkoxy inférieur, halogéno et cyano, et leurs sels d'addition d'acides pharmaceutiquement acceptables; et n a la valeur 0, 1 ou 2; et

W est un groupe alkyle ayant 1 à 7 atomes de carbone; sous réserve que R^3 ne soit pas l'hydrogène lorsque R^1 et R^2 sont des groupes méthoxy et que W est un groupe méthyle;

qui consiste à acyler un composé de formule




(XI)

dans laquelle R^1 , R^2 et R^3 sont tels que définis ci-dessus.



2. Procédé suivant la revendication 1, pour la préparation d'un composé de formule (II)'



dans laquelle R^1 , R^2 , R^3 et W sont tels que définis dans la revendication 1.

3. Procédé suivant la revendication 2, dans lequel R^1 et R^2 sont des groupes alkoxy inférieurs ayant 1 à 6 atomes de carbone.

4. Procédé suivant la revendication 3, dans lequel R^3 est choisi entre les radicaux fluoro, chloro et bromo.


5. Procédé suivant la revendication 3, dans lequel R^3 est le radical cyano.

6. Procédé suivant la revendication 4, pour la préparation du 6-chloro-2,3-diméthoxy-1,4-acétyloxy-naphtalène.

7. Procédé suivant la revendication 4, pour la préparation du 6-chloro-2,3-di-n-butoxy-1,4-acétyloxy-naphtalène.


8. Procédé suivant la revendication 2, dans lequel R^1 et R^2 sont des groupes alkylthio inférieurs ayant 1 à 6 atomes de carbone.

9. Procédé suivant l'une quelconque des revendications 1 à 8, impliquant comme matière de départ un composé de formule (VI):



dans laquelle R^1 , R^2 et R^3 sont tels que définis; cette matière de départ étant convertie en un composé de formule (XI).

10. Procédé de préparation d'une composition sous une forme qui convient à l'administration topique pour soulager l'état de psoriasis, cette composition comprenant un support non toxique pharmaceutiquement acceptable et une quantité atténuant le psoriasis d'un composé de formule



dans laquelle:

R^1 et R^2 sont des groupes alkoxy inférieurs ayant 1 à 6 atomes de carbone ou des groupes alkylthio inférieurs ayant 1 à 6 atomes de carbone;

R^3 représente l'hydrogène, un groupe alkyle inférieur ayant 1 à 6 atomes de carbone, un groupe alkoxy inférieur ayant 1 à 6 atomes de carbone, un groupe phényle éventuellement substitué, un groupe phényl-(alkyle inférieur) éventuellement substitué, un groupe phényl-(alkoxy inférieur) éventuellement substitué, un groupe amino, alkylamino inférieur, di(alkyle inférieur)amino, halogéno, cyano ou $S(O)_nR$ où R est un radical alkyle inférieur ayant 1 à 6 atomes de carbone; un groupe phényle éventuellement substitué; un groupe phényl-(alkyle inférieur) éventuellement substitué; ou un groupe aryle hétérocyclique de 3 à 9 atomes dans le noyau contenant un ou deux hétéroatomes choisis entre des atomes d'azote, d'oxygène et de soufre, le groupe aryle hétérocyclique étant éventuellement substitué par un ou plusieurs substituants choisis entre des substituants alkyle inférieur, alkoxy inférieur, halogéno et cyano, et leurs sels d'addition d'acides pharmaceutiquement acceptables; et n a la valeur 0, 1 ou 2; et

W est un groupe alkyle ayant 1 à 7 atomes de carbone;

procédé qui consiste à mélanger ensemble le composé de formule (I) avec le support non toxique pharmaceutiquement acceptable.

